person · Reporting owner

Foley Todd

Disclosed activity across 13 companies

Tapewire entity: 2482
SEC CIK: 0001473930

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Aktis Oncology, Inc.AKTS · Entity 4711	Director · 10% owner	January 12, 2026	January 14, 2026
Dyne Therapeutics, Inc.DYN · Entity 3948	10% owner	September 21, 2020	September 23, 2020
Oncorus, Inc.ONCR · Entity 112213	10% owner	October 06, 2020	October 08, 2020
RHYTHM PHARMACEUTICALS, INC.RYTM · Entity 3693	Director	March 15, 2021	March 16, 2021
Repare Therapeutics Inc.RPTX · Entity 68433	Director	June 08, 2023	June 12, 2023
TURMERIC ACQUISITION CORP.TMPM · Entity 139875	President	October 15, 2020	October 15, 2020
Werewolf Therapeutics, Inc.HOWL · Entity 7244	10% owner	March 27, 2025	April 30, 2025

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Aktis Oncology, Inc.

Report date January 12, 2026 · Filed January 14, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectSee Footnote	597,391	Reported balance After 2026-01-12 transaction · row 1 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 1 · 2026-01-12 · Conversion · Acquired 597,391 · Balance 597,391 F1: The shares of common stock were issued upon conversion as follows: 556,810 by MPM BioVentures 2018, L.P. ("BV 2018"), 29,593 by MPM BioVentures 2018 (B), L.P. ("BV 2018(B)") and 10,988 by MPM Asset Management Investors BV2018 LLC ("AM BV2018"). MPM BioVentures 2018 GP LLC and MPM BioVentures 2018 LLC ("BV2018 LLC") are the direct and indirect general partners of BV 2018 and BV 2018(B). BV 2018 LLC is the manager of AM BV2018. The Reporting Person is a managing director of BV 2018 LLC. F2: Each share of Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 3.8044-for-1 basis into the number of shares of Common Stock shown in Column 7 without payment of further consideration upon the closing of the initial public offering of the Issuer's Common Stock. The Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock had no expiration date. F3: The Reporting Persons disclaim beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. F4: The shares are held as follows: 556,810 by BV 2018, 29,593 by BV 2018(B) and 10,988 by AM BV2018.
Common StockSEC Table I · non-derivative	IndirectSee Footnote	3,285,661	Reported balance After 2026-01-12 transaction · row 2 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 2 · 2026-01-12 · Conversion · Acquired 2,688,270 · Balance 3,285,661 F5: The shares of common stock were issued upon conversion as follows: 2,505,648 by BV 2018, 133,170 by BV 2018(B) and 49,452 by AM BV2018. F2: Each share of Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 3.8044-for-1 basis into the number of shares of Common Stock shown in Column 7 without payment of further consideration upon the closing of the initial public offering of the Issuer's Common Stock. The Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock had no expiration date. F3: The Reporting Persons disclaim beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. F6: The shares are held as follows: 3,062,458 by BV 2018, 162,763 by BV 2018(B) and 60,440 by AM BV2018.
Common StockSEC Table I · non-derivative	IndirectSee Footnote	4,002,533	Reported balance After 2026-01-12 transaction · row 3 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 3 · 2026-01-12 · Conversion · Acquired 716,872 · Balance 4,002,533 F7: The shares of common stock were issued upon conversion as follows: 668,173 by BV 2018, 35,512 by BV 2018(B) and 13,187 by AM BV2018. F2: Each share of Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 3.8044-for-1 basis into the number of shares of Common Stock shown in Column 7 without payment of further consideration upon the closing of the initial public offering of the Issuer's Common Stock. The Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock had no expiration date. F3: The Reporting Persons disclaim beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. F8: The shares are held as follows: 3,730,631 by BV 2018, 198,275 by BV 2018(B) and 73,627 by AM BV2018.
Common StockSEC Table I · non-derivative	IndirectSee Footnote	4,235,403	Reported balance After 2026-01-12 transaction · row 4 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 4 · 2026-01-12 · Purchase · Acquired 232,870 · Balance 4,235,403 F9: The shares were purchased as follows: 219,897 by BV 2018, 8,689 by BV 2018(B) and 4,284 by AM BV2018. F3: The Reporting Persons disclaim beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. F10: The shares are held as follows: 3,950,528 by BV 2018, 206,964 by BV 2018(B) and 77,911 by AM BV2018.
Series Seed Redeemable Convertible Preferred StockSEC Table II · derivative / convertible security	IndirectSee Footnote	0	Reported balance After 2026-01-12 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2026-01-12 · Conversion · Disposed 2,272,727 · Balance 0 F2: Each share of Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 3.8044-for-1 basis into the number of shares of Common Stock shown in Column 7 without payment of further consideration upon the closing of the initial public offering of the Issuer's Common Stock. The Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock had no expiration date. F1: The shares of common stock were issued upon conversion as follows: 556,810 by MPM BioVentures 2018, L.P. ("BV 2018"), 29,593 by MPM BioVentures 2018 (B), L.P. ("BV 2018(B)") and 10,988 by MPM Asset Management Investors BV2018 LLC ("AM BV2018"). MPM BioVentures 2018 GP LLC and MPM BioVentures 2018 LLC ("BV2018 LLC") are the direct and indirect general partners of BV 2018 and BV 2018(B). BV 2018 LLC is the manager of AM BV2018. The Reporting Person is a managing director of BV 2018 LLC. F3: The Reporting Persons disclaim beneficial ownership of the securities except to the extent of his or its pecuniary interest therein.
Series A Redeemable Convertible Preferred StockSEC Table II · derivative / convertible security	IndirectSee Footnote	0	Reported balance After 2026-01-12 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2026-01-12 · Conversion · Disposed 10,227,273 · Balance 0 F2: Each share of Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 3.8044-for-1 basis into the number of shares of Common Stock shown in Column 7 without payment of further consideration upon the closing of the initial public offering of the Issuer's Common Stock. The Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock had no expiration date. F3: The Reporting Persons disclaim beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. F5: The shares of common stock were issued upon conversion as follows: 2,505,648 by BV 2018, 133,170 by BV 2018(B) and 49,452 by AM BV2018.
Series B Redeemable Convertible Preferred StockSEC Table II · derivative / convertible security	IndirectSee Footnote	0	Reported balance After 2026-01-12 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2026-01-12 · Conversion · Disposed 2,727,273 · Balance 0 F2: Each share of Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 3.8044-for-1 basis into the number of shares of Common Stock shown in Column 7 without payment of further consideration upon the closing of the initial public offering of the Issuer's Common Stock. The Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock had no expiration date. F3: The Reporting Persons disclaim beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. F7: The shares of common stock were issued upon conversion as follows: 668,173 by BV 2018, 35,512 by BV 2018(B) and 13,187 by AM BV2018.

Filing footnotes · ownership attribution and instrument terms

F1: The shares of common stock were issued upon conversion as follows: 556,810 by MPM BioVentures 2018, L.P. ("BV 2018"), 29,593 by MPM BioVentures 2018 (B), L.P. ("BV 2018(B)") and 10,988 by MPM Asset Management Investors BV2018 LLC ("AM BV2018"). MPM BioVentures 2018 GP LLC and MPM BioVentures 2018 LLC ("BV2018 LLC") are the direct and indirect general partners of BV 2018 and BV 2018(B). BV 2018 LLC is the manager of AM BV2018. The Reporting Person is a managing director of BV 2018 LLC.

F2: Each share of Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 3.8044-for-1 basis into the number of shares of Common Stock shown in Column 7 without payment of further consideration upon the closing of the initial public offering of the Issuer's Common Stock. The Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock had no expiration date.

F3: The Reporting Persons disclaim beneficial ownership of the securities except to the extent of his or its pecuniary interest therein.

F4: The shares are held as follows: 556,810 by BV 2018, 29,593 by BV 2018(B) and 10,988 by AM BV2018.

F5: The shares of common stock were issued upon conversion as follows: 2,505,648 by BV 2018, 133,170 by BV 2018(B) and 49,452 by AM BV2018.

F6: The shares are held as follows: 3,062,458 by BV 2018, 162,763 by BV 2018(B) and 60,440 by AM BV2018.

F7: The shares of common stock were issued upon conversion as follows: 668,173 by BV 2018, 35,512 by BV 2018(B) and 13,187 by AM BV2018.

F8: The shares are held as follows: 3,730,631 by BV 2018, 198,275 by BV 2018(B) and 73,627 by AM BV2018.

F9: The shares were purchased as follows: 219,897 by BV 2018, 8,689 by BV 2018(B) and 4,284 by AM BV2018.

F10: The shares are held as follows: 3,950,528 by BV 2018, 206,964 by BV 2018(B) and 77,911 by AM BV2018.

Dyne Therapeutics, Inc.

Report date September 21, 2020 · Filed September 23, 2020

Jointly reported with MPM BIOVENTURES 2018, L.P., MPM BIOVENTURES 2018 (B), L.P., MPM ASSET MANAGEMENT INVESTORS BV2018 LLC, MPM BioVentures 2018 GP LLC, MPM BioVentures 2018 LLC, EVNIN LUKE, GADICKE ANSBERT

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectSee footnote	4,614,943	Reported balance After 2020-09-21 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2020-09-21 · Conversion · Acquired 4,614,943 · Balance 4,614,943 F1: On September 21, 2020, the Series A Preferred Stock automatically converted into Common Stock on a 3.3169-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F5: On September 21, 2020, the Series B Preferred Stock automatically converted into Common Stock on a 3.3169-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F2: The shares are held directly by MPM BioVentures 2018, L.P. ("BV 2018"). The general partner of BV 2018 is MPM BioVentures 2018 GP LLC ("BV 2018 GP"). MPM BioVentures 2018 LLC ("BV 2018 LLC") is the managing member of BV 2018 GP. Edward Hurwitz, Luke Evnin, Ansbert Gadicke, and Todd Foley are the Managing Directors of BV 2018 LLC. Each of BV 2018 GP, BV 2018 LLC, Edward Hurwitz, Luke Evnin, Ansbert Gadicke, and Todd Foley disclaims Section 16 beneficial ownership of the securities held by BV 2018, except to the extent of its pecuniary interest therein, if any.
Common StockSEC Table I · non-derivative	IndirectSee footnote	245,279	Reported balance After 2020-09-21 transaction · row 2 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 2 · 2020-09-21 · Conversion · Acquired 245,279 · Balance 245,279 F1: On September 21, 2020, the Series A Preferred Stock automatically converted into Common Stock on a 3.3169-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F5: On September 21, 2020, the Series B Preferred Stock automatically converted into Common Stock on a 3.3169-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F3: The shares are held directly by MPM BioVentures 2018 (B), L.P. ("BV 2018(B)"). The general partner of BV 2018(B) is BV 2018 GP. BV 2018 LLC is the managing member of BV 2018 GP. Edward Hurwitz, Luke Evnin, Ansbert Gadicke, and Todd Foley are the Managing Directors of BV 2018 LLC. Each of BV 2018 GP, BV 2018 LLC, Edward Hurwitz, Luke Evnin, Ansbert Gadicke, and Todd Foley disclaims Section 16 beneficial ownership of the securities held by BV 2018(B), except to the extent of its pecuniary interest therein, if any.
Common StockSEC Table I · non-derivative	IndirectSee footnote	91,081	Reported balance After 2020-09-21 transaction · row 3 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 3 · 2020-09-21 · Conversion · Acquired 91,081 · Balance 91,081 F1: On September 21, 2020, the Series A Preferred Stock automatically converted into Common Stock on a 3.3169-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F5: On September 21, 2020, the Series B Preferred Stock automatically converted into Common Stock on a 3.3169-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F4: The shares are held directly by MPM Asset Management Investors BV2018 LLC ("MPM Asset Management"). The manager of MPM Asset Management is BV 2018 LLC. Edward Hurwitz, Luke Evnin, Ansbert Gadicke, and Todd Foley are the Managing Directors of BV2018 LLC. Each of BV 2018 LLC, Edward Hurwitz, Luke Evnin, Ansbert Gadicke, and Todd Foley disclaims Section 16 beneficial ownership of the securities held by MPM Asset Management, except to the extent of his pecuniary interest therein, if any.
Series A Preferred StockSEC Table II · derivative / convertible security	IndirectSee footnote	0	Reported balance After 2020-09-21 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2020-09-21 · Conversion · Disposed 13,980,992 · Balance 0 F1: On September 21, 2020, the Series A Preferred Stock automatically converted into Common Stock on a 3.3169-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F2: The shares are held directly by MPM BioVentures 2018, L.P. ("BV 2018"). The general partner of BV 2018 is MPM BioVentures 2018 GP LLC ("BV 2018 GP"). MPM BioVentures 2018 LLC ("BV 2018 LLC") is the managing member of BV 2018 GP. Edward Hurwitz, Luke Evnin, Ansbert Gadicke, and Todd Foley are the Managing Directors of BV 2018 LLC. Each of BV 2018 GP, BV 2018 LLC, Edward Hurwitz, Luke Evnin, Ansbert Gadicke, and Todd Foley disclaims Section 16 beneficial ownership of the securities held by BV 2018, except to the extent of its pecuniary interest therein, if any.
Series A Preferred StockSEC Table II · derivative / convertible security	IndirectSee footnote	0	Reported balance After 2020-09-21 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2020-09-21 · Conversion · Disposed 743,076 · Balance 0 F1: On September 21, 2020, the Series A Preferred Stock automatically converted into Common Stock on a 3.3169-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F3: The shares are held directly by MPM BioVentures 2018 (B), L.P. ("BV 2018(B)"). The general partner of BV 2018(B) is BV 2018 GP. BV 2018 LLC is the managing member of BV 2018 GP. Edward Hurwitz, Luke Evnin, Ansbert Gadicke, and Todd Foley are the Managing Directors of BV 2018 LLC. Each of BV 2018 GP, BV 2018 LLC, Edward Hurwitz, Luke Evnin, Ansbert Gadicke, and Todd Foley disclaims Section 16 beneficial ownership of the securities held by BV 2018(B), except to the extent of its pecuniary interest therein, if any.
Series A Preferred StockSEC Table II · derivative / convertible security	IndirectSee footnote	0	Reported balance After 2020-09-21 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2020-09-21 · Conversion · Disposed 275,932 · Balance 0 F1: On September 21, 2020, the Series A Preferred Stock automatically converted into Common Stock on a 3.3169-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F4: The shares are held directly by MPM Asset Management Investors BV2018 LLC ("MPM Asset Management"). The manager of MPM Asset Management is BV 2018 LLC. Edward Hurwitz, Luke Evnin, Ansbert Gadicke, and Todd Foley are the Managing Directors of BV2018 LLC. Each of BV 2018 LLC, Edward Hurwitz, Luke Evnin, Ansbert Gadicke, and Todd Foley disclaims Section 16 beneficial ownership of the securities held by MPM Asset Management, except to the extent of his pecuniary interest therein, if any.
Series B Preferred StockSEC Table II · derivative / convertible security	IndirectSee footnote	0	Reported balance After 2020-09-21 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2020-09-21 · Conversion · Disposed 1,326,313 · Balance 0 F5: On September 21, 2020, the Series B Preferred Stock automatically converted into Common Stock on a 3.3169-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F2: The shares are held directly by MPM BioVentures 2018, L.P. ("BV 2018"). The general partner of BV 2018 is MPM BioVentures 2018 GP LLC ("BV 2018 GP"). MPM BioVentures 2018 LLC ("BV 2018 LLC") is the managing member of BV 2018 GP. Edward Hurwitz, Luke Evnin, Ansbert Gadicke, and Todd Foley are the Managing Directors of BV 2018 LLC. Each of BV 2018 GP, BV 2018 LLC, Edward Hurwitz, Luke Evnin, Ansbert Gadicke, and Todd Foley disclaims Section 16 beneficial ownership of the securities held by BV 2018, except to the extent of its pecuniary interest therein, if any.
Series B Preferred StockSEC Table II · derivative / convertible security	IndirectSee footnote	0	Reported balance After 2020-09-21 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2020-09-21 · Conversion · Disposed 70,492 · Balance 0 F5: On September 21, 2020, the Series B Preferred Stock automatically converted into Common Stock on a 3.3169-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F3: The shares are held directly by MPM BioVentures 2018 (B), L.P. ("BV 2018(B)"). The general partner of BV 2018(B) is BV 2018 GP. BV 2018 LLC is the managing member of BV 2018 GP. Edward Hurwitz, Luke Evnin, Ansbert Gadicke, and Todd Foley are the Managing Directors of BV 2018 LLC. Each of BV 2018 GP, BV 2018 LLC, Edward Hurwitz, Luke Evnin, Ansbert Gadicke, and Todd Foley disclaims Section 16 beneficial ownership of the securities held by BV 2018(B), except to the extent of its pecuniary interest therein, if any.
Series B Preferred StockSEC Table II · derivative / convertible security	IndirectSee footnote	0	Reported balance After 2020-09-21 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2020-09-21 · Conversion · Disposed 26,176 · Balance 0 F5: On September 21, 2020, the Series B Preferred Stock automatically converted into Common Stock on a 3.3169-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F4: The shares are held directly by MPM Asset Management Investors BV2018 LLC ("MPM Asset Management"). The manager of MPM Asset Management is BV 2018 LLC. Edward Hurwitz, Luke Evnin, Ansbert Gadicke, and Todd Foley are the Managing Directors of BV2018 LLC. Each of BV 2018 LLC, Edward Hurwitz, Luke Evnin, Ansbert Gadicke, and Todd Foley disclaims Section 16 beneficial ownership of the securities held by MPM Asset Management, except to the extent of his pecuniary interest therein, if any.

Filing footnotes · ownership attribution and instrument terms

F1: On September 21, 2020, the Series A Preferred Stock automatically converted into Common Stock on a 3.3169-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date.

F2: The shares are held directly by MPM BioVentures 2018, L.P. ("BV 2018"). The general partner of BV 2018 is MPM BioVentures 2018 GP LLC ("BV 2018 GP"). MPM BioVentures 2018 LLC ("BV 2018 LLC") is the managing member of BV 2018 GP. Edward Hurwitz, Luke Evnin, Ansbert Gadicke, and Todd Foley are the Managing Directors of BV 2018 LLC. Each of BV 2018 GP, BV 2018 LLC, Edward Hurwitz, Luke Evnin, Ansbert Gadicke, and Todd Foley disclaims Section 16 beneficial ownership of the securities held by BV 2018, except to the extent of its pecuniary interest therein, if any.

F3: The shares are held directly by MPM BioVentures 2018 (B), L.P. ("BV 2018(B)"). The general partner of BV 2018(B) is BV 2018 GP. BV 2018 LLC is the managing member of BV 2018 GP. Edward Hurwitz, Luke Evnin, Ansbert Gadicke, and Todd Foley are the Managing Directors of BV 2018 LLC. Each of BV 2018 GP, BV 2018 LLC, Edward Hurwitz, Luke Evnin, Ansbert Gadicke, and Todd Foley disclaims Section 16 beneficial ownership of the securities held by BV 2018(B), except to the extent of its pecuniary interest therein, if any.

F4: The shares are held directly by MPM Asset Management Investors BV2018 LLC ("MPM Asset Management"). The manager of MPM Asset Management is BV 2018 LLC. Edward Hurwitz, Luke Evnin, Ansbert Gadicke, and Todd Foley are the Managing Directors of BV2018 LLC. Each of BV 2018 LLC, Edward Hurwitz, Luke Evnin, Ansbert Gadicke, and Todd Foley disclaims Section 16 beneficial ownership of the securities held by MPM Asset Management, except to the extent of his pecuniary interest therein, if any.

F5: On September 21, 2020, the Series B Preferred Stock automatically converted into Common Stock on a 3.3169-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date.

Oncorus, Inc.

Report date October 06, 2020 · Filed October 08, 2020

Jointly reported with MPM BioVentures 2014, L.P., MPM BioVentures 2014 (B), L.P., MPM Asset Management Investors BV2014 LLC, MPM BioVentures 2014 LLC, MPM BioVentures 2014 GP LLC, MPM ASSET MANAGEMENT LLC

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectSee footnote	1,899,702	Reported balance After 2020-10-06 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2020-10-06 · Conversion · Acquired 1,783,879 · Balance 1,899,702 F1: Each share of Series A-1 Preferred and Series B Preferred Stock automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration, on a one-for-one basis, and had no expiration date. F2: Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. F3: The shares are held as follows: 1,382,943 by MPM BioVentures 2014, L.P. ("BV 2014"), 92,239 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 50,164 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 224,924 by MPM Sunstates Fund, L.P. ("MPM SunStates"), 33,609 by MPM Asset Management Investors Sunstates Fund LLC ("AM SunStates") and 115,823 by MPM Asset Management LLC ("AM LLC"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM SunStates Fund GP LLC and MPM SunStates GP Managing Member LLC ("SunStates GP") are the direct and indirect general partners of MPM SunStates. SunStates GP is the manager of AM SunStates. Luke Evnin, Ansbert Gadicke and Todd Foley are the managing directors of BV LLC, Luke Evnin and Anbsert Gadicke are the members of AM LLC and Ansbert Gadicke is a member of SunStates GP.
Common StockSEC Table I · non-derivative	IndirectSee footnote	2,675,677	Reported balance After 2020-10-06 transaction · row 2 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 2 · 2020-10-06 · Conversion · Acquired 775,975 · Balance 2,675,677 F1: Each share of Series A-1 Preferred and Series B Preferred Stock automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration, on a one-for-one basis, and had no expiration date. F2: Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. F4: The shares are held as follows: 2,018,001 by BV 2014, 134,595 by BV 2014(B), 73,199 by AM BV2014, 290,632 by MPM SunStates, 43,427 by AM SunStates and 115,823 by AM LLC.
Common StockSEC Table I · non-derivative	IndirectSee footnote	2,849,453	Reported balance After 2020-10-06 transaction · row 3 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 3 · 2020-10-06 · Purchase · Acquired 173,776 · Balance 2,849,453 F2: Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. F5: The shares are held as follows: 2,155,108 by BV 2014, 143,740 by BV 2014(B), 78,172 by AM BV2014, 310,251 by MPM SunStates, 46,359 by AM SunStates and 115,823 by AM LLC.
Series A-1 Preferred StockSEC Table II · derivative / convertible security	IndirectSee footnote	0	Reported balance After 2020-10-06 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2020-10-06 · Conversion · Disposed 1,783,879 · Balance 0 F1: Each share of Series A-1 Preferred and Series B Preferred Stock automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration, on a one-for-one basis, and had no expiration date. F2: Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. F6: The shares are held as follows: 1,382,943 by BV 2014, 92,239 by BV 2014(B), 50,164 by AM BV2014, 224,924 by MPM SunStates and 33,609 by AM SunStates.
Series B Preferred StockSEC Table II · derivative / convertible security	IndirectSee footnote	0	Reported balance After 2020-10-06 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2020-10-06 · Conversion · Disposed 775,975 · Balance 0 F1: Each share of Series A-1 Preferred and Series B Preferred Stock automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration, on a one-for-one basis, and had no expiration date. F2: Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. F7: The shares are held as follows: 635,058 by BV 2014, 42,356 by BV 2014(B), 23,035 by AM BV2014, 65,708 by MPM SunStates and 9,818 by AM SunStates.

Filing footnotes · ownership attribution and instrument terms

F1: Each share of Series A-1 Preferred and Series B Preferred Stock automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration, on a one-for-one basis, and had no expiration date.

F2: Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein.

F3: The shares are held as follows: 1,382,943 by MPM BioVentures 2014, L.P. ("BV 2014"), 92,239 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 50,164 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 224,924 by MPM Sunstates Fund, L.P. ("MPM SunStates"), 33,609 by MPM Asset Management Investors Sunstates Fund LLC ("AM SunStates") and 115,823 by MPM Asset Management LLC ("AM LLC"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM SunStates Fund GP LLC and MPM SunStates GP Managing Member LLC ("SunStates GP") are the direct and indirect general partners of MPM SunStates. SunStates GP is the manager of AM SunStates. Luke Evnin, Ansbert Gadicke and Todd Foley are the managing directors of BV LLC, Luke Evnin and Anbsert Gadicke are the members of AM LLC and Ansbert Gadicke is a member of SunStates GP.

F4: The shares are held as follows: 2,018,001 by BV 2014, 134,595 by BV 2014(B), 73,199 by AM BV2014, 290,632 by MPM SunStates, 43,427 by AM SunStates and 115,823 by AM LLC.

F5: The shares are held as follows: 2,155,108 by BV 2014, 143,740 by BV 2014(B), 78,172 by AM BV2014, 310,251 by MPM SunStates, 46,359 by AM SunStates and 115,823 by AM LLC.

F6: The shares are held as follows: 1,382,943 by BV 2014, 92,239 by BV 2014(B), 50,164 by AM BV2014, 224,924 by MPM SunStates and 33,609 by AM SunStates.

F7: The shares are held as follows: 635,058 by BV 2014, 42,356 by BV 2014(B), 23,035 by AM BV2014, 65,708 by MPM SunStates and 9,818 by AM SunStates.

RHYTHM PHARMACEUTICALS, INC.

Report date March 15, 2021 · Filed March 16, 2021

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectSee Footnote	909,258	Reported balance After 2021-03-15 transaction · row 1 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 1 · 2021-03-15 · Sale · Disposed 1,000,000 · Balance 909,258 F1: The shares were sold as follows: 962,604 by MPM BioVentures V, L.P. ("BV V") and 37,396 by MPM Asset Management Investors BV5 LLC ("AM BV5"). MPM BioVentures V GP LLC and MPM BioVentures V LLC ("BV LLC") are the direct and indirect general partners of BV V and BV LLC is the manager of AM BV5. The Reporting Person is a member of BV LLC. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. F2: Shares are held as follows: 875,256 by BV V and 34,002 by AM BV5. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: The shares were sold as follows: 962,604 by MPM BioVentures V, L.P. ("BV V") and 37,396 by MPM Asset Management Investors BV5 LLC ("AM BV5"). MPM BioVentures V GP LLC and MPM BioVentures V LLC ("BV LLC") are the direct and indirect general partners of BV V and BV LLC is the manager of AM BV5. The Reporting Person is a member of BV LLC. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.

F2: Shares are held as follows: 875,256 by BV V and 34,002 by AM BV5. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.

Repare Therapeutics Inc.

Report date June 08, 2023 · Filed June 12, 2023

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.66 · Expires 2033-06-07	Direct	27,200	Reported balance After 2023-06-08 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2023-06-08 · Grant · Acquired 27,200 · Balance 27,200 F1: The option will vest in equal monthly installments over twelve (12) months from the date of grant, subject to Reporting Person continuing to provide service through each such date.

Filing footnotes · ownership attribution and instrument terms

F1: The option will vest in equal monthly installments over twelve (12) months from the date of grant, subject to Reporting Person continuing to provide service through each such date.

TURMERIC ACQUISITION CORP.

Report date October 15, 2020 · Filed October 15, 2020

This filing explicitly reported no securities owned.

Werewolf Therapeutics, Inc.

Report date March 27, 2025 · Filed April 30, 2025

Jointly reported with MPM BioVentures 2014, L.P., MPM BioVentures 2014 (B), L.P., MPM BioVentures 2014 LLC, MPM BioVentures 2014 GP LLC, MPM Asset Management Investors BV2014 LLC

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectSee Footnote	3,210,756	Reported balance After 2025-03-27 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2025-03-27 · Other · Acquired 22,758 · Balance 3,210,756 F1: On March 27, 2025, the Reporting Persons exercised warrants to purchase an aggregate of 22,758 shares of the Company's Common Stock for $0.09 per share. The Reporting Persons paid the exercise price on a cashless basis, resulting in the Company's withholding of 1,963 of the warrant shares to pay the exercise price and issuing the remaining 20,795 shares. F2: The shares are held as follows: 2,915,905 by MPM BioVentures 2014, L.P. ("BV 2014"), 194,486 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)") and 100,365 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014.Todd Foley is a Managing Director of BV LLC. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein.
Common StockSEC Table I · non-derivative	IndirectSee Footnote	3,208,793	Reported balance After 2025-03-27 transaction · row 2 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 2 · 2025-03-27 · Sale · Disposed 1,963 · Balance 3,208,793 F1: On March 27, 2025, the Reporting Persons exercised warrants to purchase an aggregate of 22,758 shares of the Company's Common Stock for $0.09 per share. The Reporting Persons paid the exercise price on a cashless basis, resulting in the Company's withholding of 1,963 of the warrant shares to pay the exercise price and issuing the remaining 20,795 shares. F3: The shares are held as follows: 2,914,123 by BV 2014, 194,367 by MPM 2014(B) and 100,303 by AM BV2014. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein.
Warrant (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.09 · Expires 2025-04-09	IndirectSee Footnote	0	Reported balance After 2025-03-27 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2025-03-27 · Other · Disposed 4,015 · Balance 0 F1: On March 27, 2025, the Reporting Persons exercised warrants to purchase an aggregate of 22,758 shares of the Company's Common Stock for $0.09 per share. The Reporting Persons paid the exercise price on a cashless basis, resulting in the Company's withholding of 1,963 of the warrant shares to pay the exercise price and issuing the remaining 20,795 shares. F4: Immediately exercisable. F5: The warrants were held as follows: 3,647 by BV 2014, 243 by BV 2014(B) and 125 by AM BV 2014.
Warrant (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.09 · Expires 2025-08-13	IndirectSee Footnote	0	Reported balance After 2025-03-27 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2025-03-27 · Other · Disposed 18,743 · Balance 0 F1: On March 27, 2025, the Reporting Persons exercised warrants to purchase an aggregate of 22,758 shares of the Company's Common Stock for $0.09 per share. The Reporting Persons paid the exercise price on a cashless basis, resulting in the Company's withholding of 1,963 of the warrant shares to pay the exercise price and issuing the remaining 20,795 shares. F4: Immediately exercisable. F6: The warrants were held as follows: 17,023 by BV 2014, 1,135 by BV 2014(B) and 585 by AM BV 2014.

Filing footnotes · ownership attribution and instrument terms

F1: On March 27, 2025, the Reporting Persons exercised warrants to purchase an aggregate of 22,758 shares of the Company's Common Stock for $0.09 per share. The Reporting Persons paid the exercise price on a cashless basis, resulting in the Company's withholding of 1,963 of the warrant shares to pay the exercise price and issuing the remaining 20,795 shares.

F2: The shares are held as follows: 2,915,905 by MPM BioVentures 2014, L.P. ("BV 2014"), 194,486 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)") and 100,365 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014.Todd Foley is a Managing Director of BV LLC. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein.

F3: The shares are held as follows: 2,914,123 by BV 2014, 194,367 by MPM 2014(B) and 100,303 by AM BV2014. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein.

F4: Immediately exercisable.

F5: The warrants were held as follows: 3,647 by BV 2014, 243 by BV 2014(B) and 125 by AM BV 2014.

F6: The warrants were held as follows: 17,023 by BV 2014, 1,135 by BV 2014(B) and 585 by AM BV 2014.

Past disclosures · reporting ended (6)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

CHIASMA, INC

Report date August 05, 2021 · Filed August 05, 2021

Section 16 reporting ended · disclosed 2021-08-05. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.14	Direct	Reported balance After 2021-08-05 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2021-08-05 · Disposition to issuer · Disposed 10,000 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement") dated as of May 4, 2021, by and among Chiasma, Inc. (the "Company), Amryt Pharma plc ("Parent"), and Acorn Merger Sub, Inc., an indirect wholly-owned subsidiary of Parent ("Merger Sub") pursuant to which Merger Sub merged with and into the Company (the "Merger") with the Company surviving as an indirect wholly owned subsidiary of Parent effective as of August [5], 2021 (the "Effective Time"). F2: At the Effective Time, each option to purchase Shares (each, a "Company Option") that was outstanding and unexercised, immediately prior to the Effective Time, whether or not vested shall, by virtue of the Merger Agreement, ceased to represent a right to acquire Shares, was assumed by Parent and automatically converted into the option to purchase Parent ADSs (each an "Assumed Stock Option") shall be equal to (i) the number of Shares subject to each Company Option immediately prior to the Effective Time multiplied by (ii) the Exchange Ratio, rounded down, if necessary, to the nearest whole number of Parent ADSs, and such Assumed Stock Option shall have an exercise price per Parent ADS (rounded up to the nearest cent) equal to (a) the exercise price per Share otherwise purchasable pursuant to such Company Option divided by (b) the Exchange Ratio.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.35	Direct	Reported balance After 2021-08-05 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2021-08-05 · Disposition to issuer · Disposed 13,000 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement") dated as of May 4, 2021, by and among Chiasma, Inc. (the "Company), Amryt Pharma plc ("Parent"), and Acorn Merger Sub, Inc., an indirect wholly-owned subsidiary of Parent ("Merger Sub") pursuant to which Merger Sub merged with and into the Company (the "Merger") with the Company surviving as an indirect wholly owned subsidiary of Parent effective as of August [5], 2021 (the "Effective Time"). F2: At the Effective Time, each option to purchase Shares (each, a "Company Option") that was outstanding and unexercised, immediately prior to the Effective Time, whether or not vested shall, by virtue of the Merger Agreement, ceased to represent a right to acquire Shares, was assumed by Parent and automatically converted into the option to purchase Parent ADSs (each an "Assumed Stock Option") shall be equal to (i) the number of Shares subject to each Company Option immediately prior to the Effective Time multiplied by (ii) the Exchange Ratio, rounded down, if necessary, to the nearest whole number of Parent ADSs, and such Assumed Stock Option shall have an exercise price per Parent ADS (rounded up to the nearest cent) equal to (a) the exercise price per Share otherwise purchasable pursuant to such Company Option divided by (b) the Exchange Ratio.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.45	Direct	Reported balance After 2021-08-05 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2021-08-05 · Disposition to issuer · Disposed 13,000 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement") dated as of May 4, 2021, by and among Chiasma, Inc. (the "Company), Amryt Pharma plc ("Parent"), and Acorn Merger Sub, Inc., an indirect wholly-owned subsidiary of Parent ("Merger Sub") pursuant to which Merger Sub merged with and into the Company (the "Merger") with the Company surviving as an indirect wholly owned subsidiary of Parent effective as of August [5], 2021 (the "Effective Time"). F2: At the Effective Time, each option to purchase Shares (each, a "Company Option") that was outstanding and unexercised, immediately prior to the Effective Time, whether or not vested shall, by virtue of the Merger Agreement, ceased to represent a right to acquire Shares, was assumed by Parent and automatically converted into the option to purchase Parent ADSs (each an "Assumed Stock Option") shall be equal to (i) the number of Shares subject to each Company Option immediately prior to the Effective Time multiplied by (ii) the Exchange Ratio, rounded down, if necessary, to the nearest whole number of Parent ADSs, and such Assumed Stock Option shall have an exercise price per Parent ADS (rounded up to the nearest cent) equal to (a) the exercise price per Share otherwise purchasable pursuant to such Company Option divided by (b) the Exchange Ratio.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.98	Direct	Reported balance After 2021-08-05 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2021-08-05 · Disposition to issuer · Disposed 13,000 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement") dated as of May 4, 2021, by and among Chiasma, Inc. (the "Company), Amryt Pharma plc ("Parent"), and Acorn Merger Sub, Inc., an indirect wholly-owned subsidiary of Parent ("Merger Sub") pursuant to which Merger Sub merged with and into the Company (the "Merger") with the Company surviving as an indirect wholly owned subsidiary of Parent effective as of August [5], 2021 (the "Effective Time"). F2: At the Effective Time, each option to purchase Shares (each, a "Company Option") that was outstanding and unexercised, immediately prior to the Effective Time, whether or not vested shall, by virtue of the Merger Agreement, ceased to represent a right to acquire Shares, was assumed by Parent and automatically converted into the option to purchase Parent ADSs (each an "Assumed Stock Option") shall be equal to (i) the number of Shares subject to each Company Option immediately prior to the Effective Time multiplied by (ii) the Exchange Ratio, rounded down, if necessary, to the nearest whole number of Parent ADSs, and such Assumed Stock Option shall have an exercise price per Parent ADS (rounded up to the nearest cent) equal to (a) the exercise price per Share otherwise purchasable pursuant to such Company Option divided by (b) the Exchange Ratio.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.81	Direct	Reported balance After 2021-08-05 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2021-08-05 · Disposition to issuer · Disposed 13,000 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement") dated as of May 4, 2021, by and among Chiasma, Inc. (the "Company), Amryt Pharma plc ("Parent"), and Acorn Merger Sub, Inc., an indirect wholly-owned subsidiary of Parent ("Merger Sub") pursuant to which Merger Sub merged with and into the Company (the "Merger") with the Company surviving as an indirect wholly owned subsidiary of Parent effective as of August [5], 2021 (the "Effective Time"). F2: At the Effective Time, each option to purchase Shares (each, a "Company Option") that was outstanding and unexercised, immediately prior to the Effective Time, whether or not vested shall, by virtue of the Merger Agreement, ceased to represent a right to acquire Shares, was assumed by Parent and automatically converted into the option to purchase Parent ADSs (each an "Assumed Stock Option") shall be equal to (i) the number of Shares subject to each Company Option immediately prior to the Effective Time multiplied by (ii) the Exchange Ratio, rounded down, if necessary, to the nearest whole number of Parent ADSs, and such Assumed Stock Option shall have an exercise price per Parent ADS (rounded up to the nearest cent) equal to (a) the exercise price per Share otherwise purchasable pursuant to such Company Option divided by (b) the Exchange Ratio.

Filing footnotes · ownership attribution and instrument terms

F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement") dated as of May 4, 2021, by and among Chiasma, Inc. (the "Company), Amryt Pharma plc ("Parent"), and Acorn Merger Sub, Inc., an indirect wholly-owned subsidiary of Parent ("Merger Sub") pursuant to which Merger Sub merged with and into the Company (the "Merger") with the Company surviving as an indirect wholly owned subsidiary of Parent effective as of August [5], 2021 (the "Effective Time").

F2: At the Effective Time, each option to purchase Shares (each, a "Company Option") that was outstanding and unexercised, immediately prior to the Effective Time, whether or not vested shall, by virtue of the Merger Agreement, ceased to represent a right to acquire Shares, was assumed by Parent and automatically converted into the option to purchase Parent ADSs (each an "Assumed Stock Option") shall be equal to (i) the number of Shares subject to each Company Option immediately prior to the Effective Time multiplied by (ii) the Exchange Ratio, rounded down, if necessary, to the nearest whole number of Parent ADSs, and such Assumed Stock Option shall have an exercise price per Parent ADS (rounded up to the nearest cent) equal to (a) the exercise price per Share otherwise purchasable pursuant to such Company Option divided by (b) the Exchange Ratio.

Entrada Therapeutics, Inc.

Report date September 04, 2026 · Filed September 09, 2026

Jointly reported with MPM BioVentures 2014, L.P., EVNIN LUKE, GADICKE ANSBERT, MPM BioVentures 2014 (B), L.P., MPM Asset Management Investors BV2014 LLC, MPM BioVentures 2014 LLC, MPM BioVentures 2014 GP LLC, MPM BIOVENTURES 2018 (B), L.P., MPM ASSET MANAGEMENT INVESTORS BV2018 LLC

Section 16 reporting ended · disclosed 2026-09-09. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectSee Footnote	4,106,452	Reported balance After 2026-09-04 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2026-09-04 · Sale · Disposed 38,500 · Balance 4,106,452 F1: The shares were sold as follows: 17,482 by MPM BioVentures 2014, L.P. ("BV 2014"), 1,166 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 602 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 17,942 by MPM BioVentures 2018, L.P. ("BV 2018"), 954 by MPM BioVentures 2018 (B), L.P. ("BV 2018(B)") and 354 by MPM Asset Management Investors BV2018 LLC ("AM BV2018"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV2014 LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV2014 LLC is the manager of AM BV2014. MPM BioVentures 2018 GP LLC and MPM BioVentures 2018 LLC ("BV2018 LLC") are the direct and indirect general partners of BV 2018 and BV 2018(B). BV 2018 LLC is the manager of AM BV2018. Messrs. Evnin, Foley and Gadicke are managing directors of BV 2014 LLC and BV 2018 LLC. F2: Price represents the weighted average sale price of the shares sold. The sale price ranged from $7.01 to $7.16 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. F3: The shares are held as follows: 1,864,673 by BV 2014, 124,370 by BV 2014(B), 64,182 by AM BV2014, 1,913,743 by BV 2018, 101,714 by BV 2018(B) and 37,770 by AM BV2018. F4: Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein.
Common StockSEC Table I · non-derivative	IndirectSee Footnote	3,913,952	Reported balance After 2026-09-08 transaction · row 2 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 2 · 2026-09-08 · Sale · Disposed 192,500 · Balance 3,913,952 F5: The shares were sold as follows: 87,411 by BV 2014, 5,830 by BV 2014(B), 3,009 by AM BV2014, 89,712 by BV 2018, 4,768 by BV 2018(B) and 1,770 by AM BV2018. F6: Price represents the weighted average sale price of the shares sold. The sale price ranged from $6.97 to $7.70 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. F4: Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein. F7: The shares are held as follows: 1,777,262 by BV 2014, 118,540 by BV 2014(B), 61,173 by AM BV2014, 1,824,031 by BV 2018, 96,946 by BV 2018(B) and 36,000 by AM BV2018.
Common StockSEC Table I · non-derivative	IndirectSee Footnote	3,885,115	Reported balance After 2026-09-09 transaction · row 3 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 3 · 2026-09-09 · Sale · Disposed 28,837 · Balance 3,885,115 F8: The shares were sold as follows: 13,095 by BV 2014, 873 by BV 2014(B), 451 by AM BV2014, 13,439 by BV 2018, 714 by BV 2018(B) and 265 by AM BV2018. F9: Price represents the weighted average sale price of the shares sold. The sale price ranged from $7.02 to $7.54 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. F4: Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein. F10: The shares are held as follows: 1,764,167 by BV 2014, 117,667 by BV 2014(B), 60,722 by AM BV2014, 1,810,592 by BV 2018, 96,232 by BV 2018(B) and 35,735 by AM BV2018.

Filing footnotes · ownership attribution and instrument terms

F1: The shares were sold as follows: 17,482 by MPM BioVentures 2014, L.P. ("BV 2014"), 1,166 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 602 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 17,942 by MPM BioVentures 2018, L.P. ("BV 2018"), 954 by MPM BioVentures 2018 (B), L.P. ("BV 2018(B)") and 354 by MPM Asset Management Investors BV2018 LLC ("AM BV2018"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV2014 LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV2014 LLC is the manager of AM BV2014. MPM BioVentures 2018 GP LLC and MPM BioVentures 2018 LLC ("BV2018 LLC") are the direct and indirect general partners of BV 2018 and BV 2018(B). BV 2018 LLC is the manager of AM BV2018. Messrs. Evnin, Foley and Gadicke are managing directors of BV 2014 LLC and BV 2018 LLC.

F2: Price represents the weighted average sale price of the shares sold. The sale price ranged from $7.01 to $7.16 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.

F3: The shares are held as follows: 1,864,673 by BV 2014, 124,370 by BV 2014(B), 64,182 by AM BV2014, 1,913,743 by BV 2018, 101,714 by BV 2018(B) and 37,770 by AM BV2018.

F4: Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein.

F5: The shares were sold as follows: 87,411 by BV 2014, 5,830 by BV 2014(B), 3,009 by AM BV2014, 89,712 by BV 2018, 4,768 by BV 2018(B) and 1,770 by AM BV2018.

F6: Price represents the weighted average sale price of the shares sold. The sale price ranged from $6.97 to $7.70 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.

F7: The shares are held as follows: 1,777,262 by BV 2014, 118,540 by BV 2014(B), 61,173 by AM BV2014, 1,824,031 by BV 2018, 96,946 by BV 2018(B) and 36,000 by AM BV2018.

F8: The shares were sold as follows: 13,095 by BV 2014, 873 by BV 2014(B), 451 by AM BV2014, 13,439 by BV 2018, 714 by BV 2018(B) and 265 by AM BV2018.

F9: Price represents the weighted average sale price of the shares sold. The sale price ranged from $7.02 to $7.54 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.

F10: The shares are held as follows: 1,764,167 by BV 2014, 117,667 by BV 2014(B), 60,722 by AM BV2014, 1,810,592 by BV 2018, 96,232 by BV 2018(B) and 35,735 by AM BV2018.

Harpoon Therapeutics, Inc.

Report date April 15, 2021 · Filed April 16, 2021

Jointly reported with MPM BioVentures 2014, L.P., MPM ASSET MANAGEMENT LLC, MPM BioVentures 2014 (B), L.P., MPM Asset Management Investors BV2014 LLC, MPM BioVentures 2014 LLC, MPM BioVentures 2014 GP LLC, EVNIN LUKE

Section 16 reporting ended · disclosed 2021-04-16. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectSee Footnote	3,223,853	Reported balance After 2021-04-13 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2021-04-13 · Sale · Disposed 1,657 · Balance 3,223,853 F1: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 3/16/2021. F2: The shares were sold by MPM Asset Management LLC ("AM LLC"). F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.98 to $19.88 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4: The shares are held as follows: 2,657,097 by MPM BioVentures 2014, L.P. ("BV 2014"), 152,470 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 96,376 by MPM Asset Management Investors BV2014 LLC ("AM BV2014") and 317,910 by AM LLC. MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. Messrs. Evnin and Foley are the members of BV LLC and Mr. Evnin is a member of AM LLC. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein.
Common StockSEC Table I · non-derivative	IndirectSee Footnote	3,223,567	Reported balance After 2021-04-13 transaction · row 2 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 2 · 2021-04-13 · Sale · Disposed 286 · Balance 3,223,567 F1: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 3/16/2021. F2: The shares were sold by MPM Asset Management LLC ("AM LLC"). F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.89 to $20.50 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F6: The shares are held as follows: 2,657,097 by BV 2014, 152,470 by BV 2014(B), 96,376 by AM BV2014 and 317,624 by AM LLC. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein.
Common StockSEC Table I · non-derivative	IndirectSee Footnote	3,223,446	Reported balance After 2021-04-14 transaction · row 3 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 3 · 2021-04-14 · Sale · Disposed 121 · Balance 3,223,446 F1: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 3/16/2021. F2: The shares were sold by MPM Asset Management LLC ("AM LLC"). F7: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.44 to $20.39 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F8: The shares are held as follows: 2,657,097 by BV 2014, 152,470 by BV 2014(B), 96,376 by AM BV2014 and 317,503 by AM LLC. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein.
Common StockSEC Table I · non-derivative	IndirectSee Footnote	3,221,896	Reported balance After 2021-04-14 transaction · row 4 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 4 · 2021-04-14 · Sale · Disposed 1,550 · Balance 3,221,896 F1: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 3/16/2021. F2: The shares were sold by MPM Asset Management LLC ("AM LLC"). F9: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.52 to $21.18 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F10: The shares are held as follows: 2,657,097 by BV 2014, 152,470 by BV 2014(B), 96,376 by AM BV2014 and 315,953 by AM LLC. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein.
Common StockSEC Table I · non-derivative	IndirectSee Footnote	3,220,844	Reported balance After 2021-04-15 transaction · row 5 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 5 · 2021-04-15 · Sale · Disposed 1,052 · Balance 3,220,844 F1: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 3/16/2021. F2: The shares were sold by MPM Asset Management LLC ("AM LLC"). F11: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.15 to $20.99 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F12: The shares are held as follows: 2,657,097 by BV 2014, 152,470 by BV 2014(B), 96,376 by AM BV2014 and 314,901 by AM LLC. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 3/16/2021.

F2: The shares were sold by MPM Asset Management LLC ("AM LLC").

F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.98 to $19.88 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F4: The shares are held as follows: 2,657,097 by MPM BioVentures 2014, L.P. ("BV 2014"), 152,470 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 96,376 by MPM Asset Management Investors BV2014 LLC ("AM BV2014") and 317,910 by AM LLC. MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. Messrs. Evnin and Foley are the members of BV LLC and Mr. Evnin is a member of AM LLC. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein.

F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.89 to $20.50 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F6: The shares are held as follows: 2,657,097 by BV 2014, 152,470 by BV 2014(B), 96,376 by AM BV2014 and 317,624 by AM LLC. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein.

F7: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.44 to $20.39 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F8: The shares are held as follows: 2,657,097 by BV 2014, 152,470 by BV 2014(B), 96,376 by AM BV2014 and 317,503 by AM LLC. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein.

F9: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.52 to $21.18 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F10: The shares are held as follows: 2,657,097 by BV 2014, 152,470 by BV 2014(B), 96,376 by AM BV2014 and 315,953 by AM LLC. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein.

F11: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.15 to $20.99 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F12: The shares are held as follows: 2,657,097 by BV 2014, 152,470 by BV 2014(B), 96,376 by AM BV2014 and 314,901 by AM LLC. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein.

Radius Health, Inc.

Report date September 27, 2016 · Filed September 29, 2016

Jointly reported with MPM BioVentures IV LLC, Scopa James Paul, MPM BioVentures IV GP LLC, MPM Bio IV NVS Strategic Fund LP, KAILIAN VAUGHN M

Section 16 reporting ended · disclosed 2016-09-29. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectSee footnote	1,427,698	Reported balance After 2016-09-27 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2016-09-27 · Other · Disposed 713,849 · Balance 1,427,698 F1: Represents a pro-rata in-kind distribution of Common Stock of the Issuer by MPM Bio IV NVS Strategic Fund, L.P. ("MPM NVS"), without consideration to its limited partners. F2: The shares are held by MPM NVS. F3: MPM BioVentures IV GP LLC ("BV IV GP LLC") and MPM BioVentures IV LLC ("BV IV LLC") are the direct and indirect general partners of MPM NVS. Luke Evnin, Ansbert Gadicke, Todd Foley, Vaughn M. Kailian and James Paul Scopa are the members of BV IV LLC. Each reporting person disclaims beneficial ownership of the securities reported herein except to the extent of his or its respective pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: Represents a pro-rata in-kind distribution of Common Stock of the Issuer by MPM Bio IV NVS Strategic Fund, L.P. ("MPM NVS"), without consideration to its limited partners.

F2: The shares are held by MPM NVS.

F3: MPM BioVentures IV GP LLC ("BV IV GP LLC") and MPM BioVentures IV LLC ("BV IV LLC") are the direct and indirect general partners of MPM NVS. Luke Evnin, Ansbert Gadicke, Todd Foley, Vaughn M. Kailian and James Paul Scopa are the members of BV IV LLC. Each reporting person disclaims beneficial ownership of the securities reported herein except to the extent of his or its respective pecuniary interest therein.

TCR2 THERAPEUTICS INC.

Report date June 01, 2023 · Filed June 05, 2023

Jointly reported with MPM BioVentures 2014, L.P., EVNIN LUKE, MPM BioVentures 2014 (B), L.P., MPM Asset Management Investors BV2014 LLC, MPM BioVentures 2014 LLC, MPM BioVentures 2014 GP LLC, MPM ASSET MANAGEMENT LLC

Section 16 reporting ended · disclosed 2023-06-05. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectSee Footnote	0	Reported balance After 2023-06-01 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2023-06-01 · Other · Disposed 4,158,964 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of March 5, 2023, by and among TCR2 Therapeutics Inc. (the "Company"), Adaptimmune Therapeutics plc ("Parent") and CM Merger Sub, Inc., an indirect wholly-owned subsidiary of Parent ("Merger Sub"), as amended by that certain Amendment No. 1 to the Agreement and Plan of Merger, dated April 5, 2023, by and among the Company, Parent and Merger Sub (the "Merger Agreement"), pursuant to which Merger Sub merged with and into the Company (the "Merger") with the Company surviving the Merger as an indirect wholly-owned subsidiary of Parent effective as of June 1, 2023 (the "Effective Time"). F2: At the Effective Time, each issued and outstanding share of common stock of the Company (each, a "Share") (excluding any Shares held in treasury of the Company or owned, directly or indirectly, by Parent or Merger Sub immediately prior to the Effective Time) was cancelled and converted into the right to receive 1.5117 (the "Exchange Ratio") American Depositary Shares of Parent ("Parent ADS") representing six ordinary shares of Parent ("Parent Ordinary Shares"). F3: The Reporting Persons disclaim beneficial ownership of the securities except to the extent of their respective pecuniary interests therein. F4: The shares were held as follows: 3,056,272 by MPM BioVentures 2014, L.P. ("BV 2014"), 203,846 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 110,859 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 304,001 by MPM Asset Management LLC ("AM LLC"), 421,070 by MPM SunStates Fund, L.P. ("MPM SunStates") and 62,916 by MPM Asset Management Investors Sunstates Fund LLC ("AM SunStates"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B) and BV LLC is the manager of AM BV2014. MPM SunStates Fund GP LLC and MPM SunStates GP Managing Member LLC ("SunStates GP") are the direct and indirect general partners of MPM SunStates and SunStates GP is the manager of AM SunStates. Luke Evnin, Ansbert Gadicke and Todd Foley are the managing directors of BV LLC, Ansbert Gadicke is a member of SunStates GP and Luke Evnin and Anbsert Gadicke are the members of AM LLC.

Filing footnotes · ownership attribution and instrument terms

F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of March 5, 2023, by and among TCR2 Therapeutics Inc. (the "Company"), Adaptimmune Therapeutics plc ("Parent") and CM Merger Sub, Inc., an indirect wholly-owned subsidiary of Parent ("Merger Sub"), as amended by that certain Amendment No. 1 to the Agreement and Plan of Merger, dated April 5, 2023, by and among the Company, Parent and Merger Sub (the "Merger Agreement"), pursuant to which Merger Sub merged with and into the Company (the "Merger") with the Company surviving the Merger as an indirect wholly-owned subsidiary of Parent effective as of June 1, 2023 (the "Effective Time").

F2: At the Effective Time, each issued and outstanding share of common stock of the Company (each, a "Share") (excluding any Shares held in treasury of the Company or owned, directly or indirectly, by Parent or Merger Sub immediately prior to the Effective Time) was cancelled and converted into the right to receive 1.5117 (the "Exchange Ratio") American Depositary Shares of Parent ("Parent ADS") representing six ordinary shares of Parent ("Parent Ordinary Shares").

F3: The Reporting Persons disclaim beneficial ownership of the securities except to the extent of their respective pecuniary interests therein.

F4: The shares were held as follows: 3,056,272 by MPM BioVentures 2014, L.P. ("BV 2014"), 203,846 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 110,859 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 304,001 by MPM Asset Management LLC ("AM LLC"), 421,070 by MPM SunStates Fund, L.P. ("MPM SunStates") and 62,916 by MPM Asset Management Investors Sunstates Fund LLC ("AM SunStates"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B) and BV LLC is the manager of AM BV2014. MPM SunStates Fund GP LLC and MPM SunStates GP Managing Member LLC ("SunStates GP") are the direct and indirect general partners of MPM SunStates and SunStates GP is the manager of AM SunStates. Luke Evnin, Ansbert Gadicke and Todd Foley are the managing directors of BV LLC, Ansbert Gadicke is a member of SunStates GP and Luke Evnin and Anbsert Gadicke are the members of AM LLC.

iTeos Therapeutics, Inc.

Report date May 13, 2025 · Filed May 15, 2025

Jointly reported with MPM BioVentures 2014, L.P., MPM BioVentures 2014 (B), L.P., MPM Asset Management Investors BV2014 LLC, MPM BioVentures 2014 GP LLC, MPM BioVentures 2014 LLC, MPM BIOVENTURES 2018 (B), L.P., MPM ASSET MANAGEMENT INVESTORS BV2018 LLC, EVNIN LUKE

Section 16 reporting ended · disclosed 2025-05-15. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectSee Footnote	2,108,594	Reported balance After 2025-05-13 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2025-05-13 · Sale · Disposed 630,191 · Balance 2,108,594 F1: The shares were sold as follows: 355,406 by MPM BioVentures 2014, L.P. ("BV 2014"), 22,386 by MPM BioVentures 2014 (B), L.P. ("BV 2014(B)"), 12,233 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 224,467 by MPM BioVentures 2018, L.P. ("BV 2018"), 11,267 by MPM BioVentures 2018(B), L.P. ("BV 2018(B)") and 4,432 by MPM Asset Management Investors BV2018 LLC ("AM BV2018"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV 2014 LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV 2014 LLC is the manager of AM BV2014. MPM BioVentures 2018 GP LLC and MPM BioVentures 2018 LLC ("BV 2018 LLC") are the direct and indirect general partners of BV 2018 and BV 2018(B). BV 2018 LLC is the manager of AM BV2018. Messrs. Evnin and Foley are managing directors of BV 2014 LLC and BV 2018 LLC. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.73 to $8.34 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3: The shares are held as follows: 1,189,174 by BV 2014, 74,903 by BV 2014(B), 40,931 by AM BV2014, 751,056 by BV 2018, 37,699 by BV 2018(B) and 14,831 by AM BV2018. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any.

Filing footnotes · ownership attribution and instrument terms

F1: The shares were sold as follows: 355,406 by MPM BioVentures 2014, L.P. ("BV 2014"), 22,386 by MPM BioVentures 2014 (B), L.P. ("BV 2014(B)"), 12,233 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 224,467 by MPM BioVentures 2018, L.P. ("BV 2018"), 11,267 by MPM BioVentures 2018(B), L.P. ("BV 2018(B)") and 4,432 by MPM Asset Management Investors BV2018 LLC ("AM BV2018"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV 2014 LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV 2014 LLC is the manager of AM BV2014. MPM BioVentures 2018 GP LLC and MPM BioVentures 2018 LLC ("BV 2018 LLC") are the direct and indirect general partners of BV 2018 and BV 2018(B). BV 2018 LLC is the manager of AM BV2018. Messrs. Evnin and Foley are managing directors of BV 2014 LLC and BV 2018 LLC.

F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.73 to $8.34 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3: The shares are held as follows: 1,189,174 by BV 2014, 74,903 by BV 2014(B), 40,931 by AM BV2014, 751,056 by BV 2018, 37,699 by BV 2018(B) and 14,831 by AM BV2018. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
September 08, 2021 Filed Sep 8, 2021 23:13 UTC	iTeos Therapeutics, Inc. ITOS · Entity 75965	SaleCommon Stock	940	$29.10	$27,354.00	Disclosure SEC source: 0001209191-21-055210 · doc4.xml · nonDerivative · entry 4 MPM BioVentures 2014, L.P. · CIK 0001609492 · 10% owner EVNIN LUKE · CIK 0001134657 · 10% owner Foley Todd · CIK 0001473930 · 10% owner MPM BioVentures 2014 (B), L.P. · CIK 0001609493 · 10% owner MPM Asset Management Investors BV2014 LLC · CIK 0001609495 · 10% owner MPM BioVentures 2014 LLC · CIK 0001765021 · 10% owner MPM BioVentures 2014 GP LLC · CIK 0001765091 · 10% owner MPM BIOVENTURES 2018 (B), L.P. · CIK 0001729504 · 10% owner MPM ASSET MANAGEMENT INVESTORS BV2018 LLC · CIK 0001734817 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 3,591,881 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1. F11 · shares: The shares were sold as follows: 560 by BV 2014, 19 by AM BV2014, 354 by BV 2018 and 7 by AM BV2018. F12 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.04 to $29.21 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F13 · ownership.nature: The shares are held as follows: 2,043,510 by BV 2014, 107,713 by BV 2014(B), 70,337 by AM BV2014, 1,290,637 by BV 2018, 54,213 by BV 2018(B) and 25,471 by AM BV2018. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. Page Read SEC document
September 08, 2021 Filed Sep 8, 2021 23:13 UTC	iTeos Therapeutics, Inc. ITOS · Entity 75965	SaleCommon Stock	11,152	$28.61	$319,058.72	Disclosure SEC source: 0001209191-21-055210 · doc4.xml · nonDerivative · entry 3 MPM BioVentures 2014, L.P. · CIK 0001609492 · 10% owner EVNIN LUKE · CIK 0001134657 · 10% owner Foley Todd · CIK 0001473930 · 10% owner MPM BioVentures 2014 (B), L.P. · CIK 0001609493 · 10% owner MPM Asset Management Investors BV2014 LLC · CIK 0001609495 · 10% owner MPM BioVentures 2014 LLC · CIK 0001765021 · 10% owner MPM BioVentures 2014 GP LLC · CIK 0001765091 · 10% owner MPM BIOVENTURES 2018 (B), L.P. · CIK 0001729504 · 10% owner MPM ASSET MANAGEMENT INVESTORS BV2018 LLC · CIK 0001734817 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 3,592,821 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1. F8 · shares: The shares were sold as follows: 6,644 by BV 2014, 229 by AM BV2014, 4,196 by BV 2018 and 83 by AM BV2018. F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.02 to $29.01 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F10 · ownership.nature: The shares are held as follows: 2,044,070 by BV 2014, 107,713 by BV 2014(B), 70,356 by AM BV2014, 1,290,991 by BV 2018, 54,213 by BV 2018(B) and 25,478 by AM BV2018. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. Read SEC document
September 07, 2021 Filed Sep 8, 2021 23:13 UTC	iTeos Therapeutics, Inc. ITOS · Entity 75965	OtherCommon Stock	31,340	$0.00	$0.00	Disclosure SEC source: 0001209191-21-055210 · doc4.xml · nonDerivative · entry 2 MPM BioVentures 2014, L.P. · CIK 0001609492 · 10% owner EVNIN LUKE · CIK 0001134657 · 10% owner Foley Todd · CIK 0001473930 · 10% owner MPM BioVentures 2014 (B), L.P. · CIK 0001609493 · 10% owner MPM Asset Management Investors BV2014 LLC · CIK 0001609495 · 10% owner MPM BioVentures 2014 LLC · CIK 0001765021 · 10% owner MPM BioVentures 2014 GP LLC · CIK 0001765091 · 10% owner MPM BIOVENTURES 2018 (B), L.P. · CIK 0001729504 · 10% owner MPM ASSET MANAGEMENT INVESTORS BV2018 LLC · CIK 0001734817 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 3,603,793 F5 · kind: Represents a pro rata in-kind distribution from BV 2014(B) and BV 2018(B) to its respectve limited partners for no consideration. F6 · shares: The shares were distributed as follows: 20,848 by BV 2014(B) and 10,492 by AM BV 2018(B). F7 · ownership.nature: The shares are held as follows: 2,050,714 by BV 2014, 107,713 by BV 2014(B), 70,585 by AM BV2014, 1,295,187 by BV 2018, 54,213 by BV 2018(B) and 25,561 by AM BV2018. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. Read SEC document
September 07, 2021 Filed Sep 8, 2021 23:13 UTC	iTeos Therapeutics, Inc. ITOS · Entity 75965	SaleCommon Stock	30,474	$29.18	$889,231.32	Disclosure SEC source: 0001209191-21-055210 · doc4.xml · nonDerivative · entry 1 MPM BioVentures 2014, L.P. · CIK 0001609492 · 10% owner EVNIN LUKE · CIK 0001134657 · 10% owner Foley Todd · CIK 0001473930 · 10% owner MPM BioVentures 2014 (B), L.P. · CIK 0001609493 · 10% owner MPM Asset Management Investors BV2014 LLC · CIK 0001609495 · 10% owner MPM BioVentures 2014 LLC · CIK 0001765021 · 10% owner MPM BioVentures 2014 GP LLC · CIK 0001765091 · 10% owner MPM BIOVENTURES 2018 (B), L.P. · CIK 0001729504 · 10% owner MPM ASSET MANAGEMENT INVESTORS BV2018 LLC · CIK 0001734817 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 3,635,313 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1. F2 · shares: The shares were sold as follows: 18,156 by MPM BioVentures 2014, L.P. ("BV 2014"), 625 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 11,467 by MPM BioVentures 2018, L.P. ("BV 2018") and 226 by MPM Asset Management Investors BV2018 LLC ("AM BV2018"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV 2014 LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV 2014 LLC is the manager of AM BV2014. MPM BioVentures 2018 GP LLC and MPM BioVentures 2018 LLC ("BV 2018 LLC") are the direct and indirect general partners of BV 2018 and BV 2018(B). BV 2018 LLC is the manager of AM BV2018. Messrs. Evnin and Foley are managing directors of BV 2014 LLC and BV 2018 LLC. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.89 to $29.64 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4 · ownership.nature: The shares are held as follows: 2,050,714 by BV 2014, 128,561 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 70,585 by AM BV2014, 1,295,187 by BV 2018, 64,705 by MPM BioVentures 2018(B), L.P. ("BV 2018(B)") and 25,561 by AM BV2018. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. Read SEC document
August 05, 2021 Filed Aug 5, 2021 21:29 UTC	CHIASMA, INC CHMA · Entity 136487	Disposition to issuerStock Option (Right to Buy) · Derivative	13,000	$0.00 Strike: $5.81	$0.00	Disclosure SEC source: 0001209191-21-050016 · doc4.xml · derivative · entry 5 Foley Todd · CIK 0001473930 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 13,000 shares Expires not disclosed F1 · kind: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement") dated as of May 4, 2021, by and among Chiasma, Inc. (the "Company), Amryt Pharma plc ("Parent"), and Acorn Merger Sub, Inc., an indirect wholly-owned subsidiary of Parent ("Merger Sub") pursuant to which Merger Sub merged with and into the Company (the "Merger") with the Company surviving as an indirect wholly owned subsidiary of Parent effective as of August [5], 2021 (the "Effective Time"). F2 · kind: At the Effective Time, each option to purchase Shares (each, a "Company Option") that was outstanding and unexercised, immediately prior to the Effective Time, whether or not vested shall, by virtue of the Merger Agreement, ceased to represent a right to acquire Shares, was assumed by Parent and automatically converted into the option to purchase Parent ADSs (each an "Assumed Stock Option") shall be equal to (i) the number of Shares subject to each Company Option immediately prior to the Effective Time multiplied by (ii) the Exchange Ratio, rounded down, if necessary, to the nearest whole number of Parent ADSs, and such Assumed Stock Option shall have an exercise price per Parent ADS (rounded up to the nearest cent) equal to (a) the exercise price per Share otherwise purchasable pursuant to such Company Option divided by (b) the Exchange Ratio. F2 · derivative.exercise_date: At the Effective Time, each option to purchase Shares (each, a "Company Option") that was outstanding and unexercised, immediately prior to the Effective Time, whether or not vested shall, by virtue of the Merger Agreement, ceased to represent a right to acquire Shares, was assumed by Parent and automatically converted into the option to purchase Parent ADSs (each an "Assumed Stock Option") shall be equal to (i) the number of Shares subject to each Company Option immediately prior to the Effective Time multiplied by (ii) the Exchange Ratio, rounded down, if necessary, to the nearest whole number of Parent ADSs, and such Assumed Stock Option shall have an exercise price per Parent ADS (rounded up to the nearest cent) equal to (a) the exercise price per Share otherwise purchasable pursuant to such Company Option divided by (b) the Exchange Ratio. F2 · derivative.expiration_date: At the Effective Time, each option to purchase Shares (each, a "Company Option") that was outstanding and unexercised, immediately prior to the Effective Time, whether or not vested shall, by virtue of the Merger Agreement, ceased to represent a right to acquire Shares, was assumed by Parent and automatically converted into the option to purchase Parent ADSs (each an "Assumed Stock Option") shall be equal to (i) the number of Shares subject to each Company Option immediately prior to the Effective Time multiplied by (ii) the Exchange Ratio, rounded down, if necessary, to the nearest whole number of Parent ADSs, and such Assumed Stock Option shall have an exercise price per Parent ADS (rounded up to the nearest cent) equal to (a) the exercise price per Share otherwise purchasable pursuant to such Company Option divided by (b) the Exchange Ratio. Read SEC document
August 05, 2021 Filed Aug 5, 2021 21:29 UTC	CHIASMA, INC CHMA · Entity 136487	Disposition to issuerStock Option (Right to Buy) · Derivative	13,000	$0.00 Strike: $7.98	$0.00	Disclosure SEC source: 0001209191-21-050016 · doc4.xml · derivative · entry 4 Foley Todd · CIK 0001473930 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 13,000 shares Expires not disclosed F1 · kind: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement") dated as of May 4, 2021, by and among Chiasma, Inc. (the "Company), Amryt Pharma plc ("Parent"), and Acorn Merger Sub, Inc., an indirect wholly-owned subsidiary of Parent ("Merger Sub") pursuant to which Merger Sub merged with and into the Company (the "Merger") with the Company surviving as an indirect wholly owned subsidiary of Parent effective as of August [5], 2021 (the "Effective Time"). F2 · kind: At the Effective Time, each option to purchase Shares (each, a "Company Option") that was outstanding and unexercised, immediately prior to the Effective Time, whether or not vested shall, by virtue of the Merger Agreement, ceased to represent a right to acquire Shares, was assumed by Parent and automatically converted into the option to purchase Parent ADSs (each an "Assumed Stock Option") shall be equal to (i) the number of Shares subject to each Company Option immediately prior to the Effective Time multiplied by (ii) the Exchange Ratio, rounded down, if necessary, to the nearest whole number of Parent ADSs, and such Assumed Stock Option shall have an exercise price per Parent ADS (rounded up to the nearest cent) equal to (a) the exercise price per Share otherwise purchasable pursuant to such Company Option divided by (b) the Exchange Ratio. F2 · derivative.exercise_date: At the Effective Time, each option to purchase Shares (each, a "Company Option") that was outstanding and unexercised, immediately prior to the Effective Time, whether or not vested shall, by virtue of the Merger Agreement, ceased to represent a right to acquire Shares, was assumed by Parent and automatically converted into the option to purchase Parent ADSs (each an "Assumed Stock Option") shall be equal to (i) the number of Shares subject to each Company Option immediately prior to the Effective Time multiplied by (ii) the Exchange Ratio, rounded down, if necessary, to the nearest whole number of Parent ADSs, and such Assumed Stock Option shall have an exercise price per Parent ADS (rounded up to the nearest cent) equal to (a) the exercise price per Share otherwise purchasable pursuant to such Company Option divided by (b) the Exchange Ratio. F2 · derivative.expiration_date: At the Effective Time, each option to purchase Shares (each, a "Company Option") that was outstanding and unexercised, immediately prior to the Effective Time, whether or not vested shall, by virtue of the Merger Agreement, ceased to represent a right to acquire Shares, was assumed by Parent and automatically converted into the option to purchase Parent ADSs (each an "Assumed Stock Option") shall be equal to (i) the number of Shares subject to each Company Option immediately prior to the Effective Time multiplied by (ii) the Exchange Ratio, rounded down, if necessary, to the nearest whole number of Parent ADSs, and such Assumed Stock Option shall have an exercise price per Parent ADS (rounded up to the nearest cent) equal to (a) the exercise price per Share otherwise purchasable pursuant to such Company Option divided by (b) the Exchange Ratio. Read SEC document
August 05, 2021 Filed Aug 5, 2021 21:29 UTC	CHIASMA, INC CHMA · Entity 136487	Disposition to issuerStock Option (Right to Buy) · Derivative	13,000	$0.00 Strike: $1.45	$0.00	Disclosure SEC source: 0001209191-21-050016 · doc4.xml · derivative · entry 3 Foley Todd · CIK 0001473930 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 13,000 shares Expires not disclosed F1 · kind: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement") dated as of May 4, 2021, by and among Chiasma, Inc. (the "Company), Amryt Pharma plc ("Parent"), and Acorn Merger Sub, Inc., an indirect wholly-owned subsidiary of Parent ("Merger Sub") pursuant to which Merger Sub merged with and into the Company (the "Merger") with the Company surviving as an indirect wholly owned subsidiary of Parent effective as of August [5], 2021 (the "Effective Time"). F2 · kind: At the Effective Time, each option to purchase Shares (each, a "Company Option") that was outstanding and unexercised, immediately prior to the Effective Time, whether or not vested shall, by virtue of the Merger Agreement, ceased to represent a right to acquire Shares, was assumed by Parent and automatically converted into the option to purchase Parent ADSs (each an "Assumed Stock Option") shall be equal to (i) the number of Shares subject to each Company Option immediately prior to the Effective Time multiplied by (ii) the Exchange Ratio, rounded down, if necessary, to the nearest whole number of Parent ADSs, and such Assumed Stock Option shall have an exercise price per Parent ADS (rounded up to the nearest cent) equal to (a) the exercise price per Share otherwise purchasable pursuant to such Company Option divided by (b) the Exchange Ratio. F2 · derivative.exercise_date: At the Effective Time, each option to purchase Shares (each, a "Company Option") that was outstanding and unexercised, immediately prior to the Effective Time, whether or not vested shall, by virtue of the Merger Agreement, ceased to represent a right to acquire Shares, was assumed by Parent and automatically converted into the option to purchase Parent ADSs (each an "Assumed Stock Option") shall be equal to (i) the number of Shares subject to each Company Option immediately prior to the Effective Time multiplied by (ii) the Exchange Ratio, rounded down, if necessary, to the nearest whole number of Parent ADSs, and such Assumed Stock Option shall have an exercise price per Parent ADS (rounded up to the nearest cent) equal to (a) the exercise price per Share otherwise purchasable pursuant to such Company Option divided by (b) the Exchange Ratio. F2 · derivative.expiration_date: At the Effective Time, each option to purchase Shares (each, a "Company Option") that was outstanding and unexercised, immediately prior to the Effective Time, whether or not vested shall, by virtue of the Merger Agreement, ceased to represent a right to acquire Shares, was assumed by Parent and automatically converted into the option to purchase Parent ADSs (each an "Assumed Stock Option") shall be equal to (i) the number of Shares subject to each Company Option immediately prior to the Effective Time multiplied by (ii) the Exchange Ratio, rounded down, if necessary, to the nearest whole number of Parent ADSs, and such Assumed Stock Option shall have an exercise price per Parent ADS (rounded up to the nearest cent) equal to (a) the exercise price per Share otherwise purchasable pursuant to such Company Option divided by (b) the Exchange Ratio. Read SEC document
August 05, 2021 Filed Aug 5, 2021 21:29 UTC	CHIASMA, INC CHMA · Entity 136487	Disposition to issuerStock Option (Right to Buy) · Derivative	13,000	$0.00 Strike: $1.35	$0.00	Disclosure SEC source: 0001209191-21-050016 · doc4.xml · derivative · entry 2 Foley Todd · CIK 0001473930 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 13,000 shares Expires not disclosed F1 · kind: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement") dated as of May 4, 2021, by and among Chiasma, Inc. (the "Company), Amryt Pharma plc ("Parent"), and Acorn Merger Sub, Inc., an indirect wholly-owned subsidiary of Parent ("Merger Sub") pursuant to which Merger Sub merged with and into the Company (the "Merger") with the Company surviving as an indirect wholly owned subsidiary of Parent effective as of August [5], 2021 (the "Effective Time"). F2 · kind: At the Effective Time, each option to purchase Shares (each, a "Company Option") that was outstanding and unexercised, immediately prior to the Effective Time, whether or not vested shall, by virtue of the Merger Agreement, ceased to represent a right to acquire Shares, was assumed by Parent and automatically converted into the option to purchase Parent ADSs (each an "Assumed Stock Option") shall be equal to (i) the number of Shares subject to each Company Option immediately prior to the Effective Time multiplied by (ii) the Exchange Ratio, rounded down, if necessary, to the nearest whole number of Parent ADSs, and such Assumed Stock Option shall have an exercise price per Parent ADS (rounded up to the nearest cent) equal to (a) the exercise price per Share otherwise purchasable pursuant to such Company Option divided by (b) the Exchange Ratio. F2 · derivative.exercise_date: At the Effective Time, each option to purchase Shares (each, a "Company Option") that was outstanding and unexercised, immediately prior to the Effective Time, whether or not vested shall, by virtue of the Merger Agreement, ceased to represent a right to acquire Shares, was assumed by Parent and automatically converted into the option to purchase Parent ADSs (each an "Assumed Stock Option") shall be equal to (i) the number of Shares subject to each Company Option immediately prior to the Effective Time multiplied by (ii) the Exchange Ratio, rounded down, if necessary, to the nearest whole number of Parent ADSs, and such Assumed Stock Option shall have an exercise price per Parent ADS (rounded up to the nearest cent) equal to (a) the exercise price per Share otherwise purchasable pursuant to such Company Option divided by (b) the Exchange Ratio. F2 · derivative.expiration_date: At the Effective Time, each option to purchase Shares (each, a "Company Option") that was outstanding and unexercised, immediately prior to the Effective Time, whether or not vested shall, by virtue of the Merger Agreement, ceased to represent a right to acquire Shares, was assumed by Parent and automatically converted into the option to purchase Parent ADSs (each an "Assumed Stock Option") shall be equal to (i) the number of Shares subject to each Company Option immediately prior to the Effective Time multiplied by (ii) the Exchange Ratio, rounded down, if necessary, to the nearest whole number of Parent ADSs, and such Assumed Stock Option shall have an exercise price per Parent ADS (rounded up to the nearest cent) equal to (a) the exercise price per Share otherwise purchasable pursuant to such Company Option divided by (b) the Exchange Ratio. Read SEC document
August 05, 2021 Filed Aug 5, 2021 21:29 UTC	CHIASMA, INC CHMA · Entity 136487	Disposition to issuerStock Option (Right to Buy) · Derivative	10,000	$0.00 Strike: $3.14	$0.00	Disclosure SEC source: 0001209191-21-050016 · doc4.xml · derivative · entry 1 Foley Todd · CIK 0001473930 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires not disclosed F1 · kind: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement") dated as of May 4, 2021, by and among Chiasma, Inc. (the "Company), Amryt Pharma plc ("Parent"), and Acorn Merger Sub, Inc., an indirect wholly-owned subsidiary of Parent ("Merger Sub") pursuant to which Merger Sub merged with and into the Company (the "Merger") with the Company surviving as an indirect wholly owned subsidiary of Parent effective as of August [5], 2021 (the "Effective Time"). F2 · kind: At the Effective Time, each option to purchase Shares (each, a "Company Option") that was outstanding and unexercised, immediately prior to the Effective Time, whether or not vested shall, by virtue of the Merger Agreement, ceased to represent a right to acquire Shares, was assumed by Parent and automatically converted into the option to purchase Parent ADSs (each an "Assumed Stock Option") shall be equal to (i) the number of Shares subject to each Company Option immediately prior to the Effective Time multiplied by (ii) the Exchange Ratio, rounded down, if necessary, to the nearest whole number of Parent ADSs, and such Assumed Stock Option shall have an exercise price per Parent ADS (rounded up to the nearest cent) equal to (a) the exercise price per Share otherwise purchasable pursuant to such Company Option divided by (b) the Exchange Ratio. F2 · derivative.exercise_date: At the Effective Time, each option to purchase Shares (each, a "Company Option") that was outstanding and unexercised, immediately prior to the Effective Time, whether or not vested shall, by virtue of the Merger Agreement, ceased to represent a right to acquire Shares, was assumed by Parent and automatically converted into the option to purchase Parent ADSs (each an "Assumed Stock Option") shall be equal to (i) the number of Shares subject to each Company Option immediately prior to the Effective Time multiplied by (ii) the Exchange Ratio, rounded down, if necessary, to the nearest whole number of Parent ADSs, and such Assumed Stock Option shall have an exercise price per Parent ADS (rounded up to the nearest cent) equal to (a) the exercise price per Share otherwise purchasable pursuant to such Company Option divided by (b) the Exchange Ratio. F2 · derivative.expiration_date: At the Effective Time, each option to purchase Shares (each, a "Company Option") that was outstanding and unexercised, immediately prior to the Effective Time, whether or not vested shall, by virtue of the Merger Agreement, ceased to represent a right to acquire Shares, was assumed by Parent and automatically converted into the option to purchase Parent ADSs (each an "Assumed Stock Option") shall be equal to (i) the number of Shares subject to each Company Option immediately prior to the Effective Time multiplied by (ii) the Exchange Ratio, rounded down, if necessary, to the nearest whole number of Parent ADSs, and such Assumed Stock Option shall have an exercise price per Parent ADS (rounded up to the nearest cent) equal to (a) the exercise price per Share otherwise purchasable pursuant to such Company Option divided by (b) the Exchange Ratio. Read SEC document
July 12, 2021 Filed Jul 13, 2021 20:22 UTC	Repare Therapeutics Inc. RPTX · Entity 68433	SaleCommon Shares	313	$34.10	$10,673.30	Disclosure SEC source: 0001209191-21-046493 · doc4.xml · nonDerivative · entry 3 Foley Todd · CIK 0001473930 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 2,242,636 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 3/31/2021. F8 · shares: The shares were sold as follows: 303 by BV 2014 and 10 by AM BV2014. F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.055 to $34.135 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F10 · ownership.nature: The shares are held as follows: 2,036,689 by BV 2014, 135,843 by BV 2014(B) and 70,104 by AM BV2014. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. Read SEC document
July 12, 2021 Filed Jul 13, 2021 20:22 UTC	Repare Therapeutics Inc. RPTX · Entity 68433	SaleCommon Shares	25,246	$33.58	$847,760.68	Disclosure SEC source: 0001209191-21-046493 · doc4.xml · nonDerivative · entry 2 Foley Todd · CIK 0001473930 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 2,242,949 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 3/31/2021. F5 · shares: The shares were sold as follows: 24,408 by BV 2014 and 838 by AM BV2014. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.05 to $34.04 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F7 · ownership.nature: The shares are held as follows: 2,036,992 by BV 2014, 135,843 by BV 2014(B) and 70,114 by AM BV2014. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. Read SEC document
July 09, 2021 Filed Jul 13, 2021 20:22 UTC	Repare Therapeutics Inc. RPTX · Entity 68433	SaleCommon Shares	1,792	$33.06	$59,243.52	Disclosure SEC source: 0001209191-21-046493 · doc4.xml · nonDerivative · entry 1 Foley Todd · CIK 0001473930 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 2,268,195 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 3/31/2021. F2 · shares: The shares were sold as follows: 1,732 by MPM BioVentures 2014, L.P. ("BV 2014") and 60 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"). F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.95 to $33.20 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4 · ownership.nature: The shares are held as follows: 2,061,400 by BV 2014, 135,843 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)") and 70,952 by AM BV2014. MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. Todd Foley is a managing director of BV LLC. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. Read SEC document
June 29, 2021 Filed Jun 30, 2021 21:26 UTC	Repare Therapeutics Inc. RPTX · Entity 68433	SaleCommon Shares	1,190	$33.29	$39,615.10	Disclosure SEC source: 0001209191-21-044005 · doc4.xml · nonDerivative · entry 3 Foley Todd · CIK 0001473930 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 2,269,987 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 3/31/2021. F5 · shares: The shares were sold as follows: 1,150 by BV 2014 and 40 by AM BV2014. F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.95 to $33.78 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F9 · ownership.nature: The shares are held as follows: 2,063,132 by BV 2014, 135,843 by BV 2014(B) and 71,012 by AM BV2014. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. Read SEC document
June 28, 2021 Filed Jun 30, 2021 21:26 UTC	Repare Therapeutics Inc. RPTX · Entity 68433	SaleCommon Shares	1,190	$34.82	$41,435.80	Disclosure SEC source: 0001209191-21-044005 · doc4.xml · nonDerivative · entry 2 Foley Todd · CIK 0001473930 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 2,271,177 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 3/31/2021. F5 · shares: The shares were sold as follows: 1,150 by BV 2014 and 40 by AM BV2014. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.60 to $35.10 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F7 · ownership.nature: The shares are held as follows: 2,064,282 by BV 2014, 135,843 by BV 2014(B) and 71,052 by AM BV2014. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. Read SEC document
June 28, 2021 Filed Jun 30, 2021 21:26 UTC	Repare Therapeutics Inc. RPTX · Entity 68433	SaleCommon Shares	6,080	$34.06	$207,084.80	Disclosure SEC source: 0001209191-21-044005 · doc4.xml · nonDerivative · entry 1 Foley Todd · CIK 0001473930 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 2,272,367 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 3/31/2021. F2 · shares: The shares were sold as follows: 5,878 by MPM BioVentures 2014, L.P. ("BV 2014") and 202 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"). F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.59 to $34.54 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4 · ownership.nature: The shares are held as follows: 2,065,432 by BV 2014, 135,843 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)") and 71,092 by AM BV2014. MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. Todd Foley is a managing director of BV LLC. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. Read SEC document
June 25, 2021 Filed Jun 28, 2021 20:08 UTC	Repare Therapeutics Inc. RPTX · Entity 68433	SaleCommon Shares	9,943	$33.51	$333,189.93	Disclosure SEC source: 0001209191-21-043473 · doc4.xml · nonDerivative · entry 2 Foley Todd · CIK 0001473930 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 2,278,447 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 3/31/2021. F5 · shares: The shares were sold as follows: 9,612 by BV 2014 and 331 by AM BV2014. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.10 to $33.98 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F7 · ownership.nature: The shares are held as follows: 2,071,310 by BV 2014, 135,843 by BV 2014(B) and 71,294 by AM BV2014. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. Read SEC document
June 24, 2021 Filed Jun 28, 2021 20:08 UTC	Repare Therapeutics Inc. RPTX · Entity 68433	SaleCommon Shares	2,697	$33.53	$90,430.41	Disclosure SEC source: 0001209191-21-043473 · doc4.xml · nonDerivative · entry 1 Foley Todd · CIK 0001473930 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 2,288,390 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 3/31/2021. F2 · shares: The shares were sold as follows: 2,607 by MPM BioVentures 2014, L.P. ("BV 2014") and 90 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"). F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.11 to $33.90 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4 · ownership.nature: The shares are held as follows: 2,080,922 by BV 2014, 135,843 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)") and 71,625 by AM BV2014. MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. Todd Foley is a managing director of BV LLC. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. Read SEC document
June 23, 2021 Filed Jun 23, 2021 21:38 UTC	Repare Therapeutics Inc. RPTX · Entity 68433	SaleCommon Shares	622	$32.98	$20,513.56	Disclosure SEC source: 0001209191-21-042802 · doc4.xml · nonDerivative · entry 5 Foley Todd · CIK 0001473930 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 2,291,087 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 3/31/2021. F14 · shares: The shares were sold as follows: 601 by BV 2014 and 21 by AM BV2014. F15 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.95 to $33.03 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F16 · ownership.nature: The shares are held as follows: 2,083,529 by BV 2014, 135,843 by BV 2014(B) and 71,715 by AM BV2014. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. Read SEC document
June 22, 2021 Filed Jun 23, 2021 21:38 UTC	Repare Therapeutics Inc. RPTX · Entity 68433	SaleCommon Shares	189	$34.09	$6,443.01	Disclosure SEC source: 0001209191-21-042802 · doc4.xml · nonDerivative · entry 4 Foley Todd · CIK 0001473930 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 2,291,709 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 3/31/2021. F11 · shares: The shares were sold as follows: 183 by BV 2014 6 by AM BV2014. F12 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.98 to $34.16 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F13 · ownership.nature: The shares are held as follows: 2,084,130 by BV 2014, 135,843 by BV 2014(B) and 71,736 by AM BV2014. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. Read SEC document
June 22, 2021 Filed Jun 23, 2021 21:38 UTC	Repare Therapeutics Inc. RPTX · Entity 68433	SaleCommon Shares	1,486	$33.36	$49,572.96	Disclosure SEC source: 0001209191-21-042802 · doc4.xml · nonDerivative · entry 3 Foley Todd · CIK 0001473930 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 2,291,898 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 3/31/2021. F8 · shares: The shares were sold as follows: 1,436 by BV 2014 and 50 by AM BV2014. F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.95 to $33.93 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F10 · ownership.nature: The shares are held as follows: 2,084,313 by BV 2014, 135,843 by BV 2014(B) and 71,742 by AM BV2014. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. Read SEC document
June 21, 2021 Filed Jun 23, 2021 21:38 UTC	Repare Therapeutics Inc. RPTX · Entity 68433	SaleCommon Shares	14,006	$34.63	$485,027.78	Disclosure SEC source: 0001209191-21-042802 · doc4.xml · nonDerivative · entry 2 Foley Todd · CIK 0001473930 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 2,293,384 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 3/31/2021. F5 · shares: The shares were sold as follows: 13,540 by BV 2014 and 466 by AM BV2014. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.39 to $34.87 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F7 · ownership.nature: The shares are held as follows: 2,085,749 by BV 2014, 135,843 by BV 2014(B) and 71,792 by AM BV2014. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. Read SEC document
June 21, 2021 Filed Jun 23, 2021 21:38 UTC	Repare Therapeutics Inc. RPTX · Entity 68433	SaleCommon Shares	2,556	$33.80	$86,392.80	Disclosure SEC source: 0001209191-21-042802 · doc4.xml · nonDerivative · entry 1 Foley Todd · CIK 0001473930 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 2,307,390 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 3/31/2021. F2 · shares: The shares were sold as follows: 2,471 by MPM BioVentures 2014, L.P. ("BV 2014") and 85 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"). F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.33 to $34.30 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4 · ownership.nature: The shares are held as follows: 2,099,289 by BV 2014, 135,843 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)") and 72,258 by AM BV2014. MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. Todd Foley is a managing director of BV LLC. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. Read SEC document
June 18, 2021 Filed Jun 21, 2021 20:08 UTC	Repare Therapeutics Inc. RPTX · Entity 68433	SaleCommon Shares	1,410	$34.03	$47,982.30	Disclosure SEC source: 0001209191-21-041948 · doc4.xml · nonDerivative · entry 4 Foley Todd · CIK 0001473930 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 2,309,946 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 3/31/2021. F11 · shares: The shares were sold as follows: 1,363 by BV 2014 and 47 by AM BV2014. F12 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.97 to $34.14 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F13 · ownership.nature: The shares are held as follows: 2,101,760 by BV 2014, 135,843 by BV 2014(B) and 72,343 by AM BV2014. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. Read SEC document
June 18, 2021 Filed Jun 21, 2021 20:08 UTC	Repare Therapeutics Inc. RPTX · Entity 68433	SaleCommon Shares	2,556	$33.46	$85,523.76	Disclosure SEC source: 0001209191-21-041948 · doc4.xml · nonDerivative · entry 3 Foley Todd · CIK 0001473930 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 2,311,356 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 3/31/2021. F8 · shares: The shares were sold as follows: 2,471 by BV 2014 and 85 by AM BV2014. F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.95 to $33.94 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F10 · ownership.nature: The shares are held as follows: 2,103,123 by BV 2014, 135,843 by BV 2014(B) and 72,390 by AM BV2014. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. Read SEC document
June 17, 2021 Filed Jun 21, 2021 20:08 UTC	Repare Therapeutics Inc. RPTX · Entity 68433	SaleCommon Shares	753	$34.12	$25,692.36	Disclosure SEC source: 0001209191-21-041948 · doc4.xml · nonDerivative · entry 2 Foley Todd · CIK 0001473930 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 2,313,912 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 3/31/2021. F5 · shares: The shares were sold as follows: 728 by BV 2014 and 25 by AM BV2014. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.07 to $34.26 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F7 · ownership.nature: The shares are held as follows: 2,105,594 by BV 2014, 135,843 by BV 2014(B) and 72,475 by AM BV2014. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. Read SEC document
June 17, 2021 Filed Jun 21, 2021 20:08 UTC	Repare Therapeutics Inc. RPTX · Entity 68433	SaleCommon Shares	13,575	$33.78	$458,563.50	Disclosure SEC source: 0001209191-21-041948 · doc4.xml · nonDerivative · entry 1 Foley Todd · CIK 0001473930 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 2,314,665 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 3/31/2021. F2 · shares: The shares were sold as follows: 13,123 by MPM BioVentures 2014, L.P. ("BV 2014") and 452 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"). F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.06 to $34.03 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4 · ownership.nature: The shares are held as follows: 2,106,322 by BV 2014, 135,843 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)") and 72,500 by AM BV2014. MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. Todd Foley is a managing director of BV LLC. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. Read SEC document
June 16, 2021 Filed Jun 16, 2021 21:10 UTC	Repare Therapeutics Inc. RPTX · Entity 68433	SaleCommon Shares	1,862	$33.33	$62,060.46	Disclosure SEC source: 0001209191-21-040963 · doc4.xml · nonDerivative · entry 2 Foley Todd · CIK 0001473930 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 2,328,240 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 3/31/2021. F5 · shares: The shares were sold as follows: 1,800 by BV 2014 and 62 by AM BV2014. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.95 to $33.66 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F7 · ownership.nature: The shares are held as follows: 2,119,445 by BV 2014, 135,843 by BV 2014(B) and 72,952 by AM BV2014. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. Read SEC document
June 14, 2021 Filed Jun 16, 2021 21:10 UTC	Repare Therapeutics Inc. RPTX · Entity 68433	SaleCommon Shares	881	$33.09	$29,152.29	Disclosure SEC source: 0001209191-21-040963 · doc4.xml · nonDerivative · entry 1 Foley Todd · CIK 0001473930 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 2,330,102 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 3/31/2021. F2 · shares: The shares were sold as follows: 852 by MPM BioVentures 2014, L.P. ("BV 2014") and 29 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"). F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.95 to $33.57 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4 · ownership.nature: The shares are held as follows: 2,121,245 by BV 2014, 135,843 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)") and 73,014 by AM BV2014. MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. Todd Foley is a managing director of BV LLC. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. Read SEC document
June 09, 2021 Filed Jun 10, 2021 20:05 UTC	Repare Therapeutics Inc. RPTX · Entity 68433	SaleCommon Shares	10,738	$34.79	$373,575.02	Disclosure SEC source: 0001209191-21-039426 · doc4.xml · nonDerivative · entry 4 Foley Todd · CIK 0001473930 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 2,330,983 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 3/31/2021. F11 · shares: The shares were sold as follows: 10,379 by BV 2014 and 359 by AM BV2014. F12 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.69 to $35.00 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F13 · ownership.nature: The shares are held as follows: 2,122,097 by BV 2014, 135,843 by BV 2014(B) and 73,043 by AM BV2014. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. Read SEC document
June 09, 2021 Filed Jun 10, 2021 20:05 UTC	Repare Therapeutics Inc. RPTX · Entity 68433	SaleCommon Shares	4,785	$34.42	$164,699.70	Disclosure SEC source: 0001209191-21-039426 · doc4.xml · nonDerivative · entry 3 Foley Todd · CIK 0001473930 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 2,341,721 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 3/31/2021. F8 · shares: The shares were sold as follows: 4,627 by BV 2014 and 158 by AM BV2014. F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.66 to $34.65 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F10 · ownership.nature: The shares are held as follows: 2,132,476 by BV 2014, 135,843 by BV 2014(B) and 73,402 by AM BV2014. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. Read SEC document
June 08, 2021 Filed Jun 10, 2021 20:05 UTC	Repare Therapeutics Inc. RPTX · Entity 68433	SaleCommon Shares	7,559	$33.41	$252,546.19	Disclosure SEC source: 0001209191-21-039426 · doc4.xml · nonDerivative · entry 2 Foley Todd · CIK 0001473930 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 2,346,506 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 3/31/2021. F5 · shares: The shares were sold as follows: 7,308 by BV 2014 and 251 by AM BV2014. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.16 to $33.93 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F7 · ownership.nature: The shares are held as follows: 2,137,103 by BV 2014, 135,843 by BV 2014(B) and 73,560 by AM BV2014. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. Read SEC document
June 08, 2021 Filed Jun 10, 2021 20:05 UTC	Repare Therapeutics Inc. RPTX · Entity 68433	SaleCommon Shares	3,985	$32.80	$130,708.00	Disclosure SEC source: 0001209191-21-039426 · doc4.xml · nonDerivative · entry 1 Foley Todd · CIK 0001473930 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 2,354,065 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 3/31/2021. F2 · shares: The shares were sold as follows: 3,852 by MPM BioVentures 2014, L.P. ("BV 2014") and 133 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"). F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.16 to $33.145 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4 · ownership.nature: The shares are held as follows: 2,144,411 by BV 2014, 135,843 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)") and 73,811 by AM BV2014. MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. Todd Foley is a managing director of BV LLC. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. Read SEC document
June 07, 2021 Filed Jun 7, 2021 22:40 UTC	Repare Therapeutics Inc. RPTX · Entity 68433	SaleCommon Shares	8,379	$32.96	$276,171.84	Disclosure SEC source: 0001209191-21-038751 · doc4.xml · nonDerivative · entry 6 Foley Todd · CIK 0001473930 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 2,358,050 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 3/31/2021. F17 · shares: The shares were sold as follows: 8,100 by BV 2014 and 279 by AM BV2014. F18 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.50 to $33.15 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F19 · ownership.nature: The shares are held as follows: 2,148,263 by BV 2014, 135,843 by BV 2014(B) and 73,944 by AM BV2014. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. Read SEC document
June 07, 2021 Filed Jun 7, 2021 22:40 UTC	Repare Therapeutics Inc. RPTX · Entity 68433	SaleCommon Shares	749	$32.25	$24,155.25	Disclosure SEC source: 0001209191-21-038751 · doc4.xml · nonDerivative · entry 5 Foley Todd · CIK 0001473930 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 2,366,429 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 3/31/2021. F14 · shares: The shares were sold as follows: 724 by BV 2014 and 25 by AM BV2014. F15 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.50 to $32.49 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F16 · ownership.nature: The shares are held as follows: 2,156,363 by BV 2014, 135,843 by BV 2014(B) and 74,223 by AM BV2014. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. Read SEC document
June 07, 2021 Filed Jun 7, 2021 22:40 UTC	Repare Therapeutics Inc. RPTX · Entity 68433	SaleCommon Shares	1,058	$30.74	$32,522.92	Disclosure SEC source: 0001209191-21-038751 · doc4.xml · nonDerivative · entry 4 Foley Todd · CIK 0001473930 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 2,367,178 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 3/31/2021. F11 · shares: The shares were sold as follows: 1,023 by BV 2014 and 35 by AM BV2014. F12 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.41 to $31.25 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F13 · ownership.nature: The shares are held as follows: 2,157,087 by BV 2014, 135,843 by BV 2014(B) and 74,248 by AM BV2014. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. Read SEC document
June 04, 2021 Filed Jun 7, 2021 22:40 UTC	Repare Therapeutics Inc. RPTX · Entity 68433	SaleCommon Shares	2,068	$31.28	$64,687.04	Disclosure SEC source: 0001209191-21-038751 · doc4.xml · nonDerivative · entry 3 Foley Todd · CIK 0001473930 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 2,368,236 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 3/31/2021. F8 · shares: The shares were sold as follows: 1,999 by BV 2014 and 69 by AM BV2014. F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.10 to $31.54 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F10 · ownership.nature: The shares are held as follows: 2,158,110 by BV 2014, 135,843 by BV 2014(B) and 74,283 by AM BV2014. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. Read SEC document
June 04, 2021 Filed Jun 7, 2021 22:40 UTC	Repare Therapeutics Inc. RPTX · Entity 68433	SaleCommon Shares	3,544	$30.80	$109,155.20	Disclosure SEC source: 0001209191-21-038751 · doc4.xml · nonDerivative · entry 2 Foley Todd · CIK 0001473930 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 2,370,304 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 3/31/2021. F5 · shares: The shares were sold as follows: 3,426 by BV 2014 and 118 by AM BV2014. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.10 to $31.09 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F7 · ownership.nature: The shares are held as follows: 2,160,109 by BV 2014, 135,843 by BV 2014(B) and 74,352 by AM BV2014. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. Read SEC document
June 03, 2021 Filed Jun 7, 2021 22:40 UTC	Repare Therapeutics Inc. RPTX · Entity 68433	SaleCommon Shares	9,824	$31.92	$313,582.08	Disclosure SEC source: 0001209191-21-038751 · doc4.xml · nonDerivative · entry 1 Foley Todd · CIK 0001473930 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 2,373,848 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 3/31/2021. F2 · shares: The shares were sold as follows: 9,497 by MPM BioVentures 2014, L.P. ("BV 2014") and 327 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"). F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.35 to $32.265 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4 · ownership.nature: The shares are held as follows: 2,163,535 by BV 2014, 135,843 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)") and 74,470 by AM BV2014. MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. Todd Foley is a managing director of BV LLC. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. Read SEC document
June 02, 2021 Filed Jun 2, 2021 21:40 UTC	Repare Therapeutics Inc. RPTX · Entity 68433	SaleCommon Shares	130	$32.42	$4,214.60	Disclosure SEC source: 0001209191-21-037345 · doc4.xml · nonDerivative · entry 4 Foley Todd · CIK 0001473930 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 2,383,672 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 3/31/2021. F11 · shares: The shares were sold as follows: 126 by BV 2014 and 4 by AM BV2014. F12 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.31 to $32.58 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F13 · ownership.nature: The shares are held as follows: 2,173,032 by BV 2014, 135,843 by BV 2014(B) and 74,797 by AM BV2014. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. Read SEC document
June 02, 2021 Filed Jun 2, 2021 21:40 UTC	Repare Therapeutics Inc. RPTX · Entity 68433	SaleCommon Shares	2,608	$31.83	$83,012.64	Disclosure SEC source: 0001209191-21-037345 · doc4.xml · nonDerivative · entry 3 Foley Todd · CIK 0001473930 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 2,383,802 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 3/31/2021. F8 · shares: The shares were sold as follows: 2,521 by BV 2014 and 87 by AM BV2014. F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.29 to $32.24 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F10 · ownership.nature: The shares are held as follows: 2,173,158 by BV 2014, 135,843 by BV 2014(B) and 74,801 by AM BV2014. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. Read SEC document
June 01, 2021 Filed Jun 2, 2021 21:40 UTC	Repare Therapeutics Inc. RPTX · Entity 68433	SaleCommon Shares	6,671	$32.50	$216,807.50	Disclosure SEC source: 0001209191-21-037345 · doc4.xml · nonDerivative · entry 2 Foley Todd · CIK 0001473930 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 2,386,410 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 3/31/2021. F5 · shares: The shares were sold as follows: 6,449 by BV 2014 and 222 by AM BV2014. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.12 to $32.98 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F7 · ownership.nature: The shares are held as follows: 2,175,679 by BV 2014, 135,843 by BV 2014(B) and 74,888 by AM BV2014. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. Read SEC document
May 28, 2021 Filed Jun 2, 2021 21:40 UTC	Repare Therapeutics Inc. RPTX · Entity 68433	SaleCommon Shares	7,377	$32.67	$241,006.59	Disclosure SEC source: 0001209191-21-037345 · doc4.xml · nonDerivative · entry 1 Foley Todd · CIK 0001473930 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 2,393,081 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 3/31/2021. F2 · shares: The shares were sold as follows: 7,131 by MPM BioVentures 2014, L.P. ("BV 2014") and 246 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"). F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.04 to $32.89 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4 · ownership.nature: The shares are held as follows: 2,182,128 by BV 2014, 135,843 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)") and 75,110 by AM BV2014. MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. Todd Foley is a managing director of BV LLC. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. Read SEC document
May 27, 2021 Filed May 27, 2021 23:55 UTC	Repare Therapeutics Inc. RPTX · Entity 68433	SaleCommon Shares	1,597	$33.16	$52,956.52	Disclosure SEC source: 0001209191-21-036354 · doc4.xml · nonDerivative · entry 6 Foley Todd · CIK 0001473930 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 2,400,458 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 3/31/2021. F16 · shares: The shares were sold as follows: 1,544 by BV 2014 and 53 by AM BV2014. F17 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.075 to $33.59 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F18 · ownership.nature: The shares are held as follows: 2,189,259 by BV 2014, 135,843 by BV 2014(B) and 75,356 by AM BV2014. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. Read SEC document
May 27, 2021 Filed May 27, 2021 23:55 UTC	Repare Therapeutics Inc. RPTX · Entity 68433	SaleCommon Shares	1,906	$32.81	$62,535.86	Disclosure SEC source: 0001209191-21-036354 · doc4.xml · nonDerivative · entry 5 Foley Todd · CIK 0001473930 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 2,402,055 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 3/31/2021. F13 · shares: The shares were sold as follows: 1,843 by BV 2014 and 63 by AM BV2014. F14 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.07 to $33.05 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F15 · ownership.nature: The shares are held as follows: 2,190,803 by BV 2014, 135,843 by BV 2014(B) and 75,409 by AM BV2014. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. Read SEC document
May 26, 2021 Filed May 27, 2021 23:55 UTC	Repare Therapeutics Inc. RPTX · Entity 68433	SaleCommon Shares	751	$33.01	$24,790.51	Disclosure SEC source: 0001209191-21-036354 · doc4.xml · nonDerivative · entry 4 Foley Todd · CIK 0001473930 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 2,403,961 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 3/31/2021. F10 · shares: The shares were sold as follows: 726 by BV 2014 and 25 by AM BV2014. F11 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.98 to $33.12 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F12 · ownership.nature: The shares are held as follows: 2,192,646 by BV 2014, 135,843 by BV 2014(B) and 75,472 by AM BV2014. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. Read SEC document
May 26, 2021 Filed May 27, 2021 23:55 UTC	Repare Therapeutics Inc. RPTX · Entity 68433	SaleCommon Shares	9,839	$32.74	$322,128.86	Disclosure SEC source: 0001209191-21-036354 · doc4.xml · nonDerivative · entry 3 Foley Todd · CIK 0001473930 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 2,404,712 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 3/31/2021. F7 · shares: The shares were sold as follows: 9,512 by BV 2014 and 327 by AM BV2014. F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.955 to $32.90 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F9 · ownership.nature: The shares are held as follows: 2,193,372 by BV 2014, 135,843 by BV 2014(B) and 75,497 by AM BV2014. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. Read SEC document
May 25, 2021 Filed May 27, 2021 23:55 UTC	Repare Therapeutics Inc. RPTX · Entity 68433	SaleCommon Shares	44	$33.59	$1,477.96	Disclosure SEC source: 0001209191-21-036354 · doc4.xml · nonDerivative · entry 2 Foley Todd · CIK 0001473930 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 2,414,551 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 3/31/2021. F5 · shares: The shares were sold as follows: 43 by BV 2014 and 1 by AM BV2014. F6 · ownership.nature: The shares are held as follows: 2,202,884 by BV 2014, 135,843 by BV 2014(B) and 75,824 by AM BV2014. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. Read SEC document
May 25, 2021 Filed May 27, 2021 23:55 UTC	Repare Therapeutics Inc. RPTX · Entity 68433	SaleCommon Shares	2,852	$32.87	$93,745.24	Disclosure SEC source: 0001209191-21-036354 · doc4.xml · nonDerivative · entry 1 Foley Todd · CIK 0001473930 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 2,414,595 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 3/31/2021. F2 · shares: The shares were sold as follows: 2,756 by MPM BioVentures 2014, L.P. ("BV 2014") and 96 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"). F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.45 to $33.32 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4 · ownership.nature: The shares are held as follows: 2,202,927 by BV 2014, 135,843 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)") and 75,825 by AM BV2014. MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. Todd Foley is a managing director of BV LLC. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. Read SEC document
May 24, 2021 Filed May 25, 2021 00:13 UTC	Repare Therapeutics Inc. RPTX · Entity 68433	SaleCommon Shares	8,219	$34.28	$281,747.32	Disclosure SEC source: 0001209191-21-035560 · doc4.xml · nonDerivative · entry 3 Foley Todd · CIK 0001473930 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 2,417,447 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 3/31/2021. F8 · shares: The shares were sold as follows: 7,945 by BV 2014 and 274 by AM BV2014. F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.60 to $34.37 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F10 · ownership.nature: The shares are held as follows: 2,205,683 by BV 2014, 135,843 by BV 2014(B) and 75,921 by AM BV2014. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. Read SEC document
May 24, 2021 Filed May 25, 2021 00:13 UTC	Repare Therapeutics Inc. RPTX · Entity 68433	SaleCommon Shares	1,563	$33.30	$52,047.90	Disclosure SEC source: 0001209191-21-035560 · doc4.xml · nonDerivative · entry 2 Foley Todd · CIK 0001473930 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 2,425,666 F1 · kind: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 3/31/2021. F5 · shares: The shares were sold as follows: 1,511 by BV 2014 and 52 by AM BV2014. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.57 to $33.56 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F7 · ownership.nature: The shares are held as follows: 2,213,628 by BV 2014, 135,843 by BV 2014(B) and 76,195 by AM BV2014. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.